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ABSTRACT 
The cysteine protease IdeS is an IgG degrading enzyme secreted by the bacterium Streptococcus pyogenes 
to evade the human immune system. In this thesis several inhibitors of IdeS have been synthesized and 
evaluated. Such inhibitors should be highly useful when elucidating the detailed mechanism of IdeS 
action. They might also have a potential as treatment of acute and severe infections caused by the bacteria. 
Further, IdeS has a therapeutic application of its own due to the proteolytic ability and an IdeS inhibitor 
might contribute during the development.  
Only irreversible, unselective inhibitors of IdeS were known five years ago. In this thesis, three strategies 
with the aim to synthesize and identify more inhibitors have been undertaken. Focus was first set on 
compounds with a substructure resembling the known inhibitors but with reversible warheads, i.e. nitrile, 
azide and aldehyde functions. The aldehyde derivatives were found to provide the first reversible 
inhibitors of IdeS. 
Then, to avoid covalent interactions and obtain more selective inhibitors, a substrate based strategy was 
undertaken. A 3-aminopiperidine fragment was used as replacement of either of the two residues adjacent 
to the scissile bond in IgG. Such fragments can be synthesized from N-protected 3-aminopiperidone and 
amino acid esters in reductive aminations in which a stereogenic center is formed. A series of di-, tri- and 
tetrapeptide analogues, together with eight peptides covering the cleavage site of IgG, were screened for 
their capacity to inhibit the cysteine proteases IdeS, SpeB and papain. Several analogues showed 
inhibition capacity, two compounds showed also high selectivity for IdeS. In contrast, none of the tested 
peptides showed any inhibition. Computational docking studies indicate that the identified IdeS peptide 
analogues and the non-active peptides do not share the same binding site in IdeS. Probably, the piperidine 
moiety hinders the inhibitor to enter the catalytic site.  
A more detailed study of the stereoselectivity in the reductive aminations affording the 3-aminopiperidine 
fragment showed that a large protecting group (trityl) together with a large reducing agent (NaBH(O-2-
ethylhexanoyl)3) gave the highest diastereomeric ratio. The highest ratio obtained was 21:79 when L-
proline methyl ester was used. The newly formed stereogenic center had the R-configuration, determined 
by chemical correlation. Computer based conformational analysis combined with Boltzmann distribution 
calculations implies an axial attack by the reducing reagent on the intermediary imine. 
To improve the potency of the two identified di- and tripeptide analogues synthetic routes to 
conformationally restricted N-containing bicyclic derivatives was undertaken in a third strategy. Five 
compounds with different bicyclic scaffolds were screened for their inhibition capacity towards IdeS and 
papain. One of the compounds was able to inhibit the first step of proteolytic cleavage of IgG by IdeS, a 
process usually completed in seconds. 
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ABBREVIATIONS 
Ac   acetyl 
AD amylase tris(3,5-dimethyl-
phenylcarbamate) 
alloc  allyloxycarbonyl 
aq.   aqueous 
ax   axial 
Boc   tert-butyloxycarbonyl 
Cbz   benzyloxycarbonyl 
config.   configuration 
dba  dibenzylidene acetone 
DCC N,N´-dicyclohexyl 
carbodiimide 
DCM  dichloromethane 
DEAD  diethyl azodicarboxylate 
DIAD   diisopropyl azodicarboxylate 
DIBAL  diisobutylaluminum 
DIPEA  diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DMF   N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
dr  diastereomeric ratio 
EDC  N-(3-dimethylaminopropyl)-
N´-ethylcarbodiimide 
Eq.  equation 
equiv  equivalents 
er  enantiomeric ratio 
Et  ethyl 
Fab   Fragment antigen binding 
Fmoc   9-fluorenylmethoxycarbonyl 
GAS   Group A Streptococcus 
h   hours 
HF   Hartree-Fock 
Bt   benzotriazole 
HTIB  [hydroxy(tosyloxy)iodo]-
benzene 
 
 
 
HPLC  high pressure liquid 
chromatography 
IdeS  Immunoglobulin G-degrading 
enzyme of S. pyogenes 
IgG   Immunoglobulin G 
Da   Dalton  
LC/MS  liquid chromatography/mass 
spectrometry 
Me  methyl 
min  minutes 
MW  microwave 
NIS  N-iodosuccinimide 
NMP  N-methyl-2-pyrrolidone 
NMR  Nuclear Magnetic Resonance 
on   over night 
OPLS  Optimized Potentials for 
Liquid Simulations 
PDB ID  Protein Data Base identity 
pip  piperidine, in this thesis 
ppm  part per million 
PRCG  Polak-Ribiere Conjugate 
Gradient 
pyBOP  (benzotriazol-1-yl-oxy)-
tripyrrolidinophosphonium 
hexafluorophosphate 
quant.   quantitative 
rac   racemic 
rt   room temperature 
RU   response units 
 
SDS-PAGE sodium dodecyl sulfate 
polyacrylamide gel 
electrophoresis 
SpeB  Streptococcal pyogenic 
exotoxin B 
SPR   Surface Plasmon Resonance 
STSS  streptococcal toxic shock 
syndrome 
t   time 
TBAF   tetrabutylammonium fluoride 
TBDMS  tert-butyldimethylsilyl 
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tBu   tert-butyl 
TFA   trifluoroacetic acid 
THF  tetrahydrofuran 
TLCK  tosyl lysyl chloromethyl 
ketone 
TPCK  tosyl phenylalanyl 
chloromethyl ketone 
Tr   trityl = trifenylmethyl 
TS   transition state 
Ts   toluene-4-sulfonyl 
Z-LVG-DAM benzyloxycarbonyl 
-LysValGly- 
diazomethylketone 
 
ABBREVIATIONS OF AMINO ACIDS 
A  Ala  Alanine 
C  Cys  Cysteine 
D  Asp  Aspartic acid 
E  Glu  Glutamic acid 
F  Phe  Phenylalanine 
G  Gly  Glycine 
H  His  Histidine 
I  Ile  Isoleucine 
K  Lys  Lysine 
L  Leu  Leucine 
M  Met  Metionine 
N  Asn  Aspargine 
P  Pro  Proline 
Q  Gln  Glutamine 
R  Arg  Arginine 
S  Ser  Serine 
T  Thr  Threonine 
V  Val  Valine 
W  Trp  Tryptophan 
Y  Tyr  Tyrosine 
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The bacterium Streptococcus pyogenes evades the human immune system and cause mild 
diseases but also life-threatening conditions. It escapes the human immune system by cleavage of 
the antibody IgG from its surface, mediated by a cysteine protease. To prevent such cleavage 
access to an inhibitor of the protease might be advantageous. The development of such an 
inhibitor for therapeutic applications starts with studies aimed to increase the knowledge about 
the enzyme and its mechanism of action. 
1. BACKGROUND 
1.2 CYSTEINE PROTEASES 
A cysteine protease is an enzyme that catalyzes hydrolysis of peptide bonds, i.e. peptide chains 
are cleaved, mediated by a nucleophilic thiol group present in the active site. 
Cysteine proteases are present in most living organisms, from protozoa, viruses and bacteria to 
plants, mammals and humans. In the MEROPS database all known proteases are classified and 
ranked based on their structural resemblance.1 Today (June 2011) there are about 700 cysteine 
proteases grouped into 89 families (C1-C89) which are further grouped into eight clans (denoted 
C followed by another letter, A-F). During the last ten years, an average of seven families has 
been registered annually. Of the eight clans the CA clan is the largest with 27 families. In this 
thesis, three enzymes from the CA clan have been investigated; IdeS (IgG degrading enzyme 
from Streptcococcus pyogenes) (C66) and SpeB (Streptococcal pyogenic exotoxin B) (C10), both 
from the same bacterium, and also the plant cysteine protease papain (C1) (FIGURE 1).  
 
FIGURE 1. IdeS2, SpeB3 and papain4 adopt a so-called papain-like fold with the catalytic site located between the 
two domains shown as Richardson diagrams.5-6  
As mentioned above, proteases catalyze the hydrolysis of peptides. In order to be able to 
hydrolyze a certain substrate, the enzyme depends on the active site to interact with the amino 
acid residues of that substrate and on the catalytic site to perform the hydrolysis. Most often a 
specific amide bond in the substrate is cleaved, that bond is called the scissile bond. The 
nomenclature used for the specific interactions between a substrate and the enzyme was 
suggested by Schechter and Berger (FIGURE 2).7-8  
SpeB
papain
IdeS
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FIGURE 2. Schematic representation of the interactions between the substrate (P = peptide) and the enzyme (S = 
subsite) in the active site. Picture modified from reference.8  
P denotes the substrate (P for peptide) and S denotes the subsites of the enzyme. The numbering 
of the peptide residues starts on both sides of the scissile bond and increases both towards the C-
terminal (P1´, P2´, P3´ and so on to the right) and towards the N-terminal (P1, P2, P3 and so on to 
the left). All numbers for the C-terminal side are primed. The subsites of the enzyme match the 
substrate, meaning that the region of the S1´-subsite interacts complementary with the P1´-side 
chain, the S2´-region with P2´-side chain and so on. If the substrate and the enzyme complement 
each other, the cysteine residue in the S1-subsite eventually attacks the carbonyl group of the P1 
residue. The attack by the S1-cysteine is the first step in the catalytic process which eventually 
leads to cleavage of a peptide chain. 
The general mechanism for such cysteine protease mediated cleavage is outlined in FIGURE 3.9 
For clarity only the cysteine residue of the enzyme is shown, here denoted as enz-S. In all 
cysteine proteases the thiol group of the cysteine residue is deprotonated by an adjacent histidine 
residue and these two residues operate together as an ion pair in a catalytic dyad. However, in 
several other cysteine proteases yet a third residue (either Glu, Asp or Asn) is important for the 
catalytic activity. The third residue interacts via hydrogen bonding to the His residue to position 
the imidazole ring or by further increasing the nucleophilicity of the thiolate anion. 
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FIGURE 3. Schematic mechanism of the hydrolysis and thus cleavage of a peptide chain mediated by a cysteine 
protease, here depicted as enz-S. 
For example, the Cys-His-Asp residues can operate in a catalytic triad. The imidazole ring of the 
His-residue mediates the protonation of the amine leaving (FIGURE 3D) and the subsequent 
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deprotonation of the water molecule (FIGURE 3E). The two tetrahedral intermediates (FIGURES 3B 
and F) are believed to be stabilized by an oxyanion hole via interactions between the negatively 
charged oxygen and one or more amino acid residues in the enzyme. This said, a general 
mechanism as described here should only be considered to be “general” as the catalytic 
mechanism for cysteine proteases is not yet fully understood in detail and may vary between 
different proteases.9-10 
In humans, as much as 26% of all proteases are cysteine proteases.11 Many physiological 
processes depend on cysteine proteases.12 For example, cathepsin B is involved in the metabolic 
degradation of peptides.13 Traditionally, cysteine proteases have been attributed to lysosomal 
activities, but as the knowledge about their physiological functions increases they are also 
considered as targets for drug development.14 For example, calpains (C2) are found in brain tissue 
where they hydrolyze peptides when activated by Ca2+ signaling.15 The physiological function of 
calpains is poorly understood but proteolytic activities causing tissue degradation in disorders 
such as stroke, cardiac ischemia and cataract have been proposed.16 Cathepsin K (C1) is involved 
in the skeleton renewing process by hydrolytic degradation of old collagen (type I).12 Imbalance 
in the degradation and reformation of the bone matrix can lead to osteoporosis, a disease with 
increased risk of bone fracture. Cathepsin K has been identified as a target for drug development 
for osteoporosis. Cathepsins are also involved in rheumatoid arthritis, a disease characterized by 
joint disorders due to inflammation and destruction of bone and cartilage. Another example of 
bioactive cysteine proteases is the caspases (C14) which are responsible for cell death 
programming (apoptosis).10 
Parasitic infections may also be treated by using cysteine proteases as targets for drug 
development.12 For example, falcipains have been considered a new potential target for treatment 
of malaria as they are involved in hemoglobin degradation. Hemoglobin hydrolysis provide 
amino acids used in the development of the parasite responsible for malaria.17 Cruzain is involved 
throughout the life cycle of the parasite responsible for Chagas disease where the host´s heart and 
nervous system are affected. 
One way of regulating an enzyme´s activity is to inhibit the same. 
 
1.2 CYSTEINE PROTEASE INHIBITORS 
An enzyme inhibitor is a substance that decreases the rate of an enzyme catalyzed reaction. 
As mentioned in the previous chapter, the thiolate anion of a cysteine protease attacks the scissile 
bond in peptides which eventually leads to a cleavage of the peptide chain.15 In order to hinder 
such cleavage an inhibitor can be used. The inhibitor binds to the enzyme and decreases its 
activity, the classification of inhibitors is based on where and how such binding occurs as well as 
the type of binding (FIGURE 4).15, 18 Inhibitors bind either into the active site as active-site directed 
inhibitors or at another site as allosteric inhibitors. An active site-directed inhibitor can either 
bind covalently or non-covalently. Covalent inhibitors are electrophiles that are attacked by the 
nucleophilic cysteine residue in the active site to form a covalent bond which prevents further 
enzymatic reactions. Non-covalent inhibitors must depend on other interactions in order to 
remain in the binding site. Electrostatic interactions such as hydrogen bonds, salt bridges, and pi-
pi interactions between aryl groups are the most important for protein recognition and binding 
with high specificity.18-19 
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active site‐directed allosteric site‐directed
covalently bound non‐covalently bound
irreversible
reversible
 
FIGURE 4. The classification of inhibitors is based on how and where they bind to the enzyme. The borders are 
sometimes difficult to draw, as the mechanism and hence the type of binding is not always known. 
Non-covalently bound inhibitors are reversible and the enzyme can be reactivated. Covalently 
bound inhibitors are either irreversible or reversible. An irreversible inhibitor reacts with the thiol 
group of the cysteine residue and blocks further modifications. For example, an alkylating agent 
may act as an irreversible inhibitor as the new bond is stable under biological conditions (FIGURE 
5). Yet, other agents may act as reversible inhibitors when the formed adduct is rather labile, for 
example the equilibrium process between an aldehyde and the enzyme can be reversed to 
eventually release the free enzyme (FIGURE 5). Alternatively, for an acylated enzyme, the enzyme 
can be reactivated upon hydrolysis (cf. FIGURE 3D). Such acylating inhibitors are sometimes 
called tight-binding inhibitors. 
 
FIGURE 5. Schematic examples of irreversible and reversible inhibitors, both halomethyl ketones and aldehydes 
form a covalent bond to the enzyme, denoted enz-S.  
The residence time is the ultimate limit for the classification of an inhibitor as either reversible or 
irreversible. If the enzyme-inhibitor adduct is stable enough to withstand hydrolysis, dilution, gel 
filtration or dialysis the inhibitor is classified as an irreversible inhibitor.15 Inhibitors can further 
be classified according to how they bind to the active site compared to the substrate.18 For 
example, the classical reversible, competitive inhibitor is competing with the substrate for the 
active site and must have higher affinity than that of the substrate in order to win. Yet another 
classification is based on the catalytic mechanism, i.e. mechanism-based inhibitors are analogues 
either of the substrate, the transition state (i.e. the tetrahedral intermediate) or the product. 
Another class worth mentioning also acting as irreversible inhibitors is the affinity labeling 
compounds. An affinity label is an electrophilic agent reacting with the active site residue and 
was historically used for the ultimate classification of the protease type. The chloromethyl 
ketones TPCK (tosyl phenylalanyl chloromethyl ketone)20 and TLCK (tosyl lysyl chloromethyl 
ketone)21 have been used as affinity labels (FIGURE 6). 
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FIGURE 6. TPCK and TLCK are covalent, irreversible inhibitors. 
Development of inhibitors targeting cysteine proteases has for long been based on converting the 
substrate into an inhibitor by replacing the P1-residue with an electrophilic moiety.22 Often, two 
to four residues of the substrate is used.13 The electrophilic functionality in such inhibitor 
structures is sometimes called the warhead.22 In 1997 and 2002, two extensive review articles 
were published listing such warheads used in cysteine protease inhibitors.15, 22 Warheads such as 
halomethyl ketones, epoxides and diazomethylketones (sometimes called diazomethane inhibitors 
and hence abbreviated DAM) connected to short peptides inhibit cysteine proteases irreversibly. 
Iodoacetate, E-6423 and Z-LVG-DAM24 are a few examples of irreversible inhibitors (FIGURE 7). 
 
FIGURE 7. Covalent irreversible inhibitors containing different electrophilic warheads. 
Iodoacetate is used for quenching enzyme reactions while testing potential inhibitors. The 
irreversible process is inevitable when the halogen atom is expelled via a nucleophilic attack by 
the thiolate anion. Depending on the enzyme the interaction between E-64 (or analogues) and the 
active site orients the inhibitor differently.22 Either C2 or C3 is attacked when the epoxide is ring-
opened via the nucleophilic attack. The detailed mechanism for Z-LVG-DAM is not yet fully 
understood.25 Events discussed are for example nucleophilic attack on the carbonyl group, 
protonation of the CH group by histidine and formation of a three-membered ring in the transition 
state before N2 is eventually released. Covalent reversible inhibitors depend on warheads such as 
aldehydes, nitriles or acylating agents, the intermediates formed differ in geometry dependent on 
the electrophile (FIGURE 8).15  
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FIGURE 8. Covalent reversible inhibitors forming enzyme adducts with different geometry. 
The enzyme and the aldehyde form an adduct which may be stabilized by the oxyanion hole in a 
similar fashion as the enzyme-substrate complex. The nitriles are said to be weaker inhibitors 
compared to aldehydes, the stabilization of the different adducts may be the explanation. A 
general example of an acylating inhibitor is the aza-peptide shown in FIGURE 8. In an aza-peptide 
one or more α-carbons have been replaced by nitrogen and most often this nitrogen is substituted, 
i.e. aza-peptides consist of aza-amino acids. The substituted nitrogen alters the 3D structure of the 
inhibitor and decreases the electronegativity of the scissile bond´s carbonyl group. Sometimes 
these changes make the adduct more difficult to hydrolyze compared to normal acyl-adducts.26  
By mining the literature, the latest trends in the development of cysteine protease inhibitors can 
be seen. In the last five years, about 52 articles within the topic “Cysteine Protease Inhibitors” 
have been published in Journal of Medicinal Chemistry and Bioorganic & Medicinal Chemistry. 
More than half of the articles (35) report newly synthesized inhibitors targeting different cysteine 
proteases such as falcipain (9 hits), cathepsin (7 hits), cruzain (5 hits) and caspase (4 hits). Most 
of the inhibitors are short peptides or peptidomimetics, only a few consist of non-peptidic 
structures and most often their inhibitory activity depends on an electrophilic warhead. Despite 
this, there are a few examples of the contrary. Non-covalent inhibitors which lack the reactive 
moiety depend instead on specific interactions which tend to be more selective. High selectivity 
means that other similar targets are not affected and such inhibitors tend to cause less 
toxicological events. For comparison, the first non-covalent inhibitors based on arylaminoethyl 
amides were reported in 2002 (cathepsin K) (FIGURE 9A). Then, non-peptidic cathepsin S 
inhibitors containing a fused piperidine/pyrazole bicyclic system were reported in 2004 (FIGURE 
9B). Also, non-peptidic 2-cyanopyrimidines have been reported to inhibit cathepsin K (FIGURE 
9C). In 2010 a caspase-1 inhibitor with a secondary amine instead of an aldehyde showed 
inhibitory activity (FIGURE 9D). 
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FIGURE 9A-D. Recently published non-covalent and nonpeptide-like cysteine protease inhibitors. 
 
 
1.3 THREE MEMBERS OF THE CA CLAN 
Papain, SpeB and IdeS are cysteine proteases catalyzing the hydrolysis of the same substrate, the 
human antibody immunoglobulin G (IgG). In this thesis the main focus is set on IdeS, whereas 
SpeB and papain have been used for selectivity studies. 
1.3.1 Papain is a plant cysteine protease found in papaya latex (Carcia papaya) in the 1870s.27 
The enzyme is used in manufacture and cooking industry.28 Papain prevents wool to shrink and is 
a known meat tenderizer as it hydrolyzes collagen. It also prevents cold haze in beer. Papain is 
the by far most studied cysteine protease and the 3D X-ray structure of the Cα backbone was 
solved already in 1968.29 Many refined structures have been deposited at the protein data bank 
since then, e.g. PDB ID: 9PAP.4 The active form of papain consists of 212 amino acids.9 
Residues Cys47 and His159 constitute the dyad responsible for the proteolytic activity, the 
enzyme is active in a pH range of 4-8. Studies of the catalytic process using one-site mutations of 
papain where Asn175 was replaced with either glutamine or alanine (i.e. N175Q and N175A) 
showed that Asn175 enhances the catalytic rate, but is not essential for the activity.30 Asn175 has 
been suggested to position His195 into orientations facilitating the catalysis during the different 
steps of the enzymatic reaction. Further, as the two catalytic residues are located on different 
domains additional amino acid residues are needed to hold the active site residues in place for the 
catalytic action. The oxyanion hole in papain consists of Gln19 and the NH-group of Cys25. 
Papain cleaves peptide chains preferentially between Arg or Phe (P1) and Gln (P1´) residues, 
most often a Leu residue is present at the P2-position but also Phe is tolerated. In fact, papain is 
able to hydrolyze a wide range of substrates and has a broad specificity.1, 31 Papain cleaves the 
human antibody IgG at position 224, between His224 and Thr225. Papain is irreversibly inhibited 
by iodoacetate, Z-LVG-DAM and E-64, the latter by attack of the epoxide at C2.22 Also TPCK 
and TLCK are inhibiting papain, but to different extent.32 In fact, the difference is as high as 20 
times favoring TLCK. Drenth et al. report that the Lys residue in TLCK is pointing towards 
Asp160 present close to the catalytic site.29 
1.3.2 SpeB (Streptococcal pyogenic exotoxin B, also called streptopain or SCP, Streptococcal 
cysteine protease) was discovered in 1945 as the first isolated cysteine protease of a prokaryotic 
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organism.33 The enzyme is secreted as a zymogen by the bacterium S. pyogenes and auto-
catalyzes cleavage into the mature SpeB, consisting of 253 residues.34-35 SpeB is involved in host-
patogen interactions and increases the invasive action of S. pyogenes by hydrolysis of human 
fibronectin and vitronectin.36 It also prevents normal functions of the human immune system by 
cleavage of M proteins and C5a peptidases. SpeB cleaves the human antibody IgG between 
residues Gly236 and Gly237 and also other antibodies, such as IgA, IgD, IgE, and IgM.37 SpeB 
shows little specificity and is able to hydrolyze peptides with Lys, Asn, Ala and Gly in the P1-
position.1, 31 In P2 most often hydrophobic residues are positioned, while the P2´-residue is most 
often Val or Phe. SpeB is irreversibly inhibited by iodoacetate, Z-LVG and E-64. 
Three 3D structures of SpeB have been deposited at the protein data bank.38 In 2000, the structure 
of the inactive zymogen (PDB ID: 1DKI) was published.34 Two years ago, two structures of the 
mature enzyme were released. The mature enzyme was either C47S-mutated (PDB ID: 2JTC)3 or 
inhibited by E-64 (PDB ID: 2UZJ).39 The first structure was determined by NMR spectroscopy 
the latter by X-ray diffraction. The inhibited enzyme mSpeB-E64 crystallizes as a dimer with an 
interacting area of 1270 Å2 between the two enzyme monomers. The authors speculate that SpeB 
is activated by forming such a dimer, as His195 is found in the correct position for catalytic 
activity only in the dimer albeit inhibited form. Indeed, the way the imidazole ring is assigned in 
the 2JTC-structure there is no hydrogen bond between Cys47Ser and His195. Possibly, by 
interconversion of the non-assignable nitrogen and carbon atoms in the imidazole ring, a 
hydrogen bond might exist.19 The two structures are shown in FIGURE 10. However, to establish 
whether the dimer hypothesis for SpeB activation is correct or just an artifact from the 
crystallization needs to be studied in more detail and is beyond the scope of the present study. 
 
FIGURE 10. 3D structures of SpeB6 A) the C47S-mutated structure (PDB ID: 2JTC); B) the E-64 inhibited structure 
(PDB ID: 2UZJ).  
1.3.3 IdeS (Immunoglobulin G-degrading enzyme of S. pyogenes, also called Mac-1) was 
discovered by two independent research teams in 2001 and 2002.40-42 As the name indicates the 
cysteine protease catalyzes the hydrolysis of the human antibody IgG.43 IdeS is secreted by S. 
pyogenes as a mature enzyme of 339 residues and is used by the bacterium as a defense 
mechanism, further discussed in the next chapter.44 
Already today IdeS has potential medical applications due to its proteolytic activity, it has been 
shown to block arthritis development induced by IgG.45 Studies in rabbits also show that IdeS 
may be used to prevent rejection after renal transplantations by its highly selective degradation of 
IgG.46 In addition, autoimmune conditions where IgG labels endogenous compounds as 
pathogenic may be treated by IdeS injected into the circulatory system. 
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Studies of the catalytic action of IdeS have been performed using one-site mutations which 
showed that four residues are involved in the catalytic process, i.e. Cys94, His262, Asp284 and 
Asp286.47 When the X-ray structure was solved, the distances between hydrogen bond donor and 
acceptor groups in C94S - His262 and His262 - Asp284 were measured to 3.5 and 2.7 Å, 
respectively, indicating that IdeS works via a catalytic triad.44 It was also seen that the oxyanion 
hole consists of Lys84 and the backbone of Cys94. The fourth residue Asp286 is also involved in 
stabilizing the oxyanion hole by interacting with the side chain of Lys84. 
Even if mature IdeS is present it does not hydrolyze peptides randomly. IdeS is strictly specific 
for its substrate and cleaves the peptide chain of IgG between Gly236 and Gly237 (further 
discussed in the next chapter).43 A wide range of potential substrates have been tested without 
detecting any cleavage products. IdeS does not even cleave short peptides resembling the IgG 
sequence. IdeS becomes irreversible inhibited by iodoacetate, Z-LVG-DAM, TPCK and TLCK 
but does not react with E-64. 
Three crystal structures of IdeS have been deposited at the protein data bank.38 Two of the 
structures are mutated forms in which the active site cysteine is replaced by either a serine 
residue, i.e. C94S (PDB ID: 1Y0A)44 or an alanine residue, i.e. C94A (PDB ID: 2AVW).2 The 
latter structure and the wild-type structure (PDB ID: 2AU1)2 were refined iteratively. 
To summarize, the three cysteine proteases (papain, SpeB and IdeS) show a similar 3D fold. IdeS 
and papain activities depend on catalytic triads, while SpeB contains a catalytic dyad. SpeB and 
papain cleave a broad spectrum of substrates while the only identified substrate of IdeS is the IgG 
antibody. IdeS and SpeB attack IgG at Gly236 while papain cleaves IgG at His224. They are all 
inhibited by the same compounds (iodoacetate, Z-LVG-DAM, TPCK and TLCK) but IdeS is not 
affected by E-64. A major feature of IdeS is the presence of the Arg259 residue in the vicinity of 
the catalytic site, this residue has to move before substrate binding. Such a residue is neither 
present in SpeB nor papain. 
 
1.4 THE BACTERIA/HOST-SYSTEM – putting it all together 
The Gram-positive bacterium Streptococcus pyogenes colonizes humans and is commonly 
present in the throat and on the skin.48 S. pyogenes is the causative agent for relatively mild 
human diseases such as pharyngitis (sore throat) and scarlatania (scarlet fever) as well as of the 
acute life-threatening conditions sepsis (presence of toxins in blood or tissue), streptococcal toxic 
shock syndrome (STSS) (hypertension and multiple organ failure) and necrotizing fasciitis 
(severe muscle breakdown). Moreover, initially mild infections can cause severe complications 
such as acute rheumatic fever which untreated can lead to serious heart infections. S. pyogenes is 
sensitive towards penicillin and shows no significant resistance. However, in the 1980s sudden 
unexplainable infections caused by S. pyogenes arose worldwide. The only treatment of the more 
severe and acute state of STSS consists of intravenous injections of the antibody immunoglobulin 
G (IgG) in high doses.49 The global burden of Group A Streptococcus (GAS) diseases is difficult 
to estimate. Population-based data has been used to calculate over 500.000 deaths annually and 
about 600.000 cases of pharyngitis due to the invasive bacteria.50 
The antibody IgG is an important part of the human immune system which signals and triggers 
phagocytosis, i.e. the removal of invading bacteria out of the body. IgG consists of four peptide 
chains folded into 12 distinct domains (FIGURE 11).51 The chains are held together by disulfide-
bridges (marked as black dots) and several sugar moieties. The two identical heavy chains 
resemble the shape of the capital letter Y. At the crotch the identical light chains are attached to 
each heavy chain. This part of IgG is called the Fab region (Fragment antigen binding). Most of 
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the domains are constant but the two at the top are variable domains. The hinge region is highly 
flexible and the residues Gly236-Gly237 and His224-Thr225 constitute the scissile bonds for 
IdeS/SpeB and papain, respectively. In one IgG molecule there is one hinge region consisting of 
two individual peptide chains. Thus, there exist two scissile bonds for each IgG antibody 
molecule. 
...EPKSCDKTHTCPPCPAPELLGGP…
 
FIGURE 11. Schematic picture of IgG with the residues in the hinge region written out.43  
The bacterium S. pyogenes protects itself by various defense systems to escape from the human 
immune system, one of these defense mechanisms is outlined in FIGURE 12.37, 52 
 
FIGURE 12. Schematic picture of the action of IdeS, modified from reference.37 On the cell wall of the bacteria the 
Y-shaped IgG binds to bacterial surface proteins (1), this signals to the immune system to remove the invading 
microorganisms. However, the bacteria secrete IdeS (indicated by a blue arrow) (2) which cleave IgG in the hinge 
region (indicated by red arrows) (3). When IgG is cleaved the signaling to macrophages to remove the bacteria out of 
the body is no longer working. Thus, the bacteria escape the human immune system. 
In FIGURE 13, the X-ray structures of IdeS and IgG are shown, in comparison IgG is a large 
protein. The magenta region of IgG indicates the flexible hinge region where IgG is cleaved by 
the cysteine proteases. 
13 
 
 
FIGURE 13. X-ray crystal structures of IdeS (left) (PDB ID: 1Y0A) and IgG (PDB ID: 1IGT)53 (right), both at the 
same scale.6  
As mention above, the mechanism of action of IdeS is not yet fully understood. Kinetic studies 
involving Hill plot analysis show that there are two cooperative binding sites present in IdeS.43 
This can be due to a dimerization of the enzyme. Cooperative binding may be explained by one 
IdeS-IgG binding event promotes another enzyme to bind to that IgG molecule. In fact, a dimeric 
structure of IdeS has been revealed by X-ray crystallography (PDB ID: 2AU1) and also detected 
when using size exclusion chromatography (FIGURE 14).2 
 
FIGURE 14. Two monomers of IdeS team up as a dimer in the crystal structure (PDB: 2AVW monomer E and F).6 
The residues from each monomer of the interface are colored in either magenta or yellow. A tunnel is seen at the 
center of the interface.  
The surface area buried when two IdeS monomers come together is reported to be as large as 
1800 Å2 for each dimer, i.e. 900 Å2 for each monomer interfacing the other monomer. However, 
the IdeS dimer hypothesis is rejected by Olsen et al. saying that the interface is too small for a 
dimer only being 830 Å2 or even 660 Å2.39 To aid the analysis of interfaces in true dimers versus 
interactions due to crystal packing, Janin et al. have used 70 examples to identify the 
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characteristic features of dimers and crystal packing complexes.54 For a dimer, features such as an 
interface of 3900 Å2, 100 residues and as much as 19 hydrogen bonds are usually seen. Weak 
dimers have, on average interfaces of 1620 Å2 (but yet smaller interaction areas have been 
reported) made up of 50 residues but only seven hydrogen bonds, whereas crystal packing 
interactions are much smaller; 570 Å2, still consisting of 48 residues and yet only five hydrogen 
bonds. Thus, if a small interface is seen together with only a few hydrogen bonds, the 
dimerization is most likely due to crystal packing and is therefore not considered biologically 
relevant. The interface of the IdeS dimer consists of maximum 19 residues, if counting also the 
residues being part of a tunnel present perpendicular through the interface. Four residues from 
one monomer are interacting with the other monomer via hydrogen bonds. In light of the features 
defined by Janin et al., the dimer hypothesis is not likely to be biologically important for IdeS. 
Further evidences lead to the same conclusion. According to Janin et al., the composition of 
residues involved in the interface can also aid the analysis. Interfaces are enriched in Met, Tyr 
and Trp, but highly polar residues such as Lys, Glu or Asp are rarely seen. Also, residues making 
contact with the same residue from the other monomer are common (as the dimer is made up of 
two identical monomers). In such pairs, Leu residues are highly represented (known as Leu 
zippers) followed by Phe, Val and Arg. However, both Arg and Glu are even more likely to 
match up in a crystal packing interface. Studying the dimer of IdeS, the upper part of the interface 
is made up by a pair of Tyr residues not interacting (FIGURE 14). Neither do the four present Leu 
residues (FIGURE 15A). 
 
FIGURE 15. Zoomed residues from FIGURE 14, A) Leu residues, represented by dots, are not interacting with the 
other monomer; B) The two Phe129 from each monomer are interacting; C) Salt-bridges are formed across the 
monomers. 
 In the lower part of the interface, pairs of both Phe and Met residues are seen. The two aromatic 
side chains of Phe129 match up in a pi-pi system with a distance of 4.2 Å (FIGURE 15B). 
However, salt bridges are seen as the polar side chains of Glu132 and Arg185 interact which 
disfavors the dimer hypothesis (FIGURE 15C). Moreover, according to Janin et al. crystals packed 
as dimers are artifacts only seen when studying structures using X-ray crystallography using 
highly concentrated solutions. On the contrary, in dilute solutions the monomers are in 
equilibrium with weak dimers, meaning not all monomers form dimers. Thus, the border between 
weak dimers and true dimers actually being biologically relevant becomes unclear. The 
dimerization is speculated to be an activation process for IdeS, as the enzyme is secreted in a 
mature form and not as a zymogen.2  
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Further, studies with mutated enzymes were used for the dimer elucidation. Results from an IdeS 
F129I mutant showed less binding between the enzyme and the substrate and also a 200-fold 
lower catalytic activity than that of the wild-type.2 This indicates that the Phe129 residue is 
important both for enzyme-substrate contact and for the catalytic process. But does it really 
indicate that the dimerization is needed for activity? Most often, proper folding of the enzyme is 
crucial for activity. Upon mutation the overall structure could be altered and thus weakly 
inactivating the enzyme anyway. However, the outcome of the Hill plot analysis could also be 
explained by the presence of an exosite in IdeS.43 An exosite means that the enzyme and IgG 
interact also at a remote site different from the catalytic site. In fact, experiments have shown that 
the product formed after papain cleavage of IgG, with the G236-G237 residues still present, is 
further hydrolyzed by IdeS. This and also the high degree of specificity observed for IdeS add 
arguments for the presence of an exosite. Finally, also the presence and function of the Arg259 
residue has to be explained as it must move in order to reveal the catalytic site for IgG before the 
proteolytic process can begin. 
Taken together, both the dimer and exosite hypotheses need to be further investigated in order to 
understand the detailed mechanism of IdeS proteolytic ability. 
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2. AIM  
The aim of this thesis was to synthesize and identify compounds with the capability to selectively 
inhibit IdeS, a bacterial cysteine protease. Such compounds could be useful in further 
investigations aiming to elucidate the mechanism of IdeS. A compound structurally similar to the 
substrate could be useful for X-ray structure determination of active IdeS. Further, a selective 
inhibitor of IdeS might aid the development of therapeutic IdeS treatments. 
In order to develop selective inhibitors of IdeS, the focus was first set to reversible inhibitors. 
Then, the overall strive was to avoid the covalent bond-dependency. Non-covalently bound 
inhibitors were aimed for in a substrate-based approach wherein peptide analogues were 
synthesized and evaluated. To increase the potency of the inhibitors the strategy to decrease their 
conformational flexibility was undertaken and bicyclic derivatives came into focus. 
In this thesis the following actions were undertaken: 
 Development of synthetic routes and synthesis of p-tosyl amino derivatives with 
reversible functions as warheads and to screen their IdeS inhibition capability (PAPER I)  
 Development of synthetic routes using the 3-aminopiperidine fragments in a substrate-
based approach, and to screen such peptide analogues for their IdeS inhibition capacities 
(PAPER III) 
 Improvement of the potencies of identified 3-aminopiperidine-based inhibitors by 
reducing the conformational flexibility by developing synthetic routes towards bicyclic 
compounds and screen those (PAPER IV) 
 Evaluation of the selectivity profile of the identified IdeS inhibitors towards the related 
cysteine proteases papain and SpeB (PAPER III, IV)  
 Investigation of the stereoselectivity in reductive aminations with 3-aminopiperidone and 
different amino acids esters used in the synthetic route to 3-aminopiperidine based peptide 
analogues (PAPER II)  
 Attempted usage of computational studies to try to understand the different inhibition 
profiles of peptides and peptide analogues (included in the work of PAPER III) 
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3. INTRODUCTION  
3.1 INTRODUCTION TO THE TPCK/TLCK ANALOGUES (PAPER I) 
The development of inhibitors against IdeS started with the aim to avoid the need of an 
irreversible covalently bound warhead. In order to find selective inhibitors, which have more 
specific interactions with the enzyme, the focus was first set to reversible inhibitors. The 
inhibition potency of TPCK and TLCK against IdeS have been reported but without detailed 
data.55, papain is affected differently by the two inhibitors.32 This fact arouses questions like: Is 
the warhead alone responsible for all inhibitory effect of IdeS? and Does the R-group substituent 
contribute to the binding to IdeS? The design of potential reversible inhibitors of IdeS was based 
on the structures of TPCK and TLCK and by decreasing the reactivity of the warhead it was 
anticipated that the contribution of the side chain would show. The p-tosylamido function was 
kept whereas both the side chain R-groups and warheads were varied (FIGURE 16). To challenge 
the need of the amino group in TLCK norleucine, also called n-butylglycine was used. The azide 
function had recently been shown to inhibit caspase-1 (cysteine proteases with a strict need for an 
Asp residue in P1-position) and was therefore included.56 The alcohol was included to challenge 
the overall need of a warhead. 
 
FIGURE 16. R-substituents and warheads used in the TPCK/TLCK analogues. All combinations were aimed for.  
3.2 INTRODUCTION TO PIPERIDINE-BASED ANALOGUES (PAPER III) 
IdeS catalyzes the hydrolysis of the peptide bond between G236 and G237 in the hinge region of 
IgG, but it cannot cleave short peptides containing the same amino acid sequence covering the 
GG sequence in IgG.44 If short peptides are not hydrolyzed, can they still interact with IdeS, 
prevent IgG to bind and thus inhibit IdeS? To answer this question a series of di-, tri- and 
tetrapeptide analogues based on either the LLGG or the LGGP sequences were synthesized and 
tested for potential inhibitory activity. In the analogues one of the two glycine residues was 
replaced by a piperidine moiety thus forming either pip236G- or Gpip237-fragments (FIGURE 17). 
The 3-aminopiperidine fragment has not been used in a peptidomimetic strategy before. As a new 
stereogenic center was introduced in the peptide analogues (marked with an asterisk in FIGURE 
17) the resulting enantiomers or diastereomers were aimed to be tested separately. Also, eight 
peptides of different length covering P4-P´4 of the IgG sequence were purchased and tested for 
their ability to inhibit IdeS. 
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FIGURE 17. In the synthesized di-, tri- or tetrapeptide analogues of the hinge sequence of IgG a piperidine moiety 
replaces either the Gly236- or Gly237-residue of the scissile bond. The new stereogenic center present in the peptide 
analogues is marked with an asterisk. 
3.3 INTRODUCTION TO BICYCLIC DERIVATIVES (PAPER IV) 
The results from the inhibition assay performed with the piperidine analogues showed that 
Lpip236G and pip236G acted as IdeS inhibitors. Therefore, in order to increase the potency a 
project was started aiming for potential inhibitors with a more rigid structure. The strategy was to 
fuse another ring onto the piperidine moiety (FIGURE 18).  
 
FIGURE 18. The substructure of pip236G was kept in the bicyclic scaffold. Another ring fused onto piperidine would 
increase the rigidity and possibly the potency of the potential bicyclic inhibitors. 
Features such as control of the stereogenic center, opportunity for elongation both C- and N-
terminally and avoidance of peptide bonds were desired. In fact, somewhat related compounds 
have been synthesized as dimers and also pentamers, so called @-tides (FIGURE 19).57-58 NMR 
spectroscopic studies of the @-tides indicate that they have hydrogen bonding capacity in a linear 
fashion, thus resembling β-strands.58 In fact, proteases have been reported to interact with 
peptides adopting extended conformations in their active site.59 
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FIGURE 19. A penta-@-tide is constituted by three amino acid residues held together by two piperidone-based 
fragments abbreviated as @. As shown, the penta-@-tide may form six hydrogen bonds to a schematic peptide. 
The two bicyclic systems shown in FIGURE 20 may have capacity to interact with a protein 
structure (such as IdeS) and thus act as inhibitors of IdeS. 
 
 
FIGURE 20. Starting points for the synthesis of bicyclic scaffolds. 
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4. SYNTHESIS 
4.1 SYNTHESIS OF TPCK/TLCK ANALOGUES (PAPER I) 
The chemistry shown in the following chapter is based on functional group transformations. For 
example, starting from an α-amino acid alcohol both the corresponding aldehyde and its higher 
homolog might be synthesized via several synthetic steps. The key step is the nitrile formation 
which introduces an additional carbon atom. 
The synthetic route to the TPCK analogues in which R represents either benzyl, n-butyl or i-
propyl is shown in SCHEME 1. Along the presentation of the reaction pathways examples from the 
literature covering similar reactions will be added and discussed. 
 
SCHEME 1. Synthetic route to TPCK analogues. Reagents and conditions: (i) TsCl (1 equiv.), Et3N, DMAP, DCM, 
0 C => rt, on; (ii) PPh3, DIAD, DCM; (iii) TsCl (2 equiv.), pyridine, DCM, 0 C => rt, 6 h; (iv) NaCN (2 equiv.), 
DMSO, 35 C, 6 h or on; (v) NaN3 (2 equiv.), DMSO, 35 C, 6 h or on; (vi) DIBAL-H in toluene, -65 C, 50 to 90 
min. 
Initially, the free amino group in L-phenylalaninol, L-norleucinol and L-valinol (1a-c) was reacted 
with tosyl chloride mediated by triethylamine and DMAP to form N-tosylated alcohols (2a-c) 
(86-95%).60 Interestingly, in the literature other amino alcohol derivatives were both N- and O-
tosylated using the same conditions. In order to afford the desired mono-tosylated product, it was 
reported that the alcohol moiety in the example shown in SCHEME 2 had to be protected prior to 
the N-tosylation and consequently deprotected afterwards.61 
 
SCHEME 2. Literature example of N-tosylation via TBDMS-protection. Reagents and conditions: (i) 1) n-BuLi, 
diethyl ether, -78 ºC; 2) TBDMSCl, diethyl ether, -78 ºC; (ii) TsCl, Et3N, DCM; (iii) TBAF x 3H2O, THF. 
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An example of a chemoselective reaction is showed in SCHEME 3 where N-tosylation is favoured 
over O-tosylation affording 11a.62 As the nitrogen is more nucleophilic the N-tosylation is much 
faster than the corresponding reaction with the alcohol and protecting group chemistry is in most 
cases not needed. However, the selectivity is highly dependent on the substrate. The 
phenylglycine derivative needed O-protection of the two alcohol functions to afford the desired 
product 11b. 
 
 
SCHEME 3. Literature example of N-tosylation without and with the need of O-bisprotection.62 Reagents and 
conditions: 11a: (i) TsCl (1.1 equiv.), Et3N (2 equiv.), DCM, 0 ºC; 11b (i) TsCl (4 equiv.), pyridine and Et3N (2 
equiv.), DCM, 15 h. 
The route to the TPCK analogues continued with attempts to convert the alcohols (2a-c) to the 
corresponding azides (3a-c) (SCHEME 1). In the literature, Mitsunobu conditions and Fmoc-
protected L-amino alcohols afforded azides (80-87%) (SCHEME 4).63 
 
SCHEME 4. Example of azide formation.63 Reagents and conditions: (i) PPh3, DEAD, HN3. 
Surprisingly, in the reactions in SCHEME 1 between 2a-c and NaN3 mediated by PPh3 and DIAD, 
aziridines 4a-c were instead formed (SCHEME 1). This was confirmed by 1H NMR spectra that 
showed no peak for the sulfonamide NH-proton. In contrast to the Fmoc-protected precursors, 
aziridine formation has been observed for several Boc-protected L-amino acids also using 
Mitsunobu conditions with yields in the 73-86% range.64 So, aziridine formation occurs with β-
amino alcohol derivatives when a sufficiently strong base promotes a nucleophilic attack by the 
nitrogen onto the β-carbon carrying a good leaving group in the right position to be expelled in an 
SN2-fashion (SCHEME 5A).65 The choice of protecting group seems to contribute to the different 
reaction outcomes. 
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SCHEME 5. A) General reaction mechanism for aziridine formation. Literature examples of aziridine formation B) 
(i) TsCl, pyridine 0 ºC, 24 h, (ii) Et3N, THF, reflux, 24 h; C) (i) LiAlH4; D) (i) PPh3, DIAD, THF. 
A good leaving group may be mesylate, sometimes tosylate and as experienced here, a phosphine 
oxide. Some literature examples of aziridine formation are given; N-trityl protected L-serinol 
benzyl ester 14 was converted to the mesylate derivative and under basic conditions (Et3N) in 
refluxing THF the aziridine 15 was formed (SCHEME 5B).66 A 4-azido pentos derivative (16) was 
reduced to the primary amine, after ring inversion the amine could expel the mesylate and the 
aziridine 17 was formed (SCHEME 5C).67 In a prolyl-threonine derivate, the amide-nitrogen 
expelled the phosphine oxide to form the aziridine 19 (SCHEME 5D).68 
With the confirmed aziridine formation in hand, attempts to compete with the intra-molecular 
ring closure reaction were made. Starting from the alcohol (2b, 2c) the reaction was performed 
with an excess of NaN3 (3 and 10 equiv.) using Mitsunobu conditions (SCHEME 1). However, the 
aziridine (4b, 4c) was still obtained as the only product. Probably, the azide ion worked as a base 
and facilitated the ring closure. 
Since both cyanide and azide ions are nucleophiles the tosyl-substituted aziridine may eventually 
be ring opened, however occasionally without satisfying regioselectivity.69 Most often, the 
unsubstituted methylene is attacked (SCHEME 6, route A) but also the substituted sterically 
hindered carbon can be attacked (route B) and then mixtures of regioisomers are formed. Of 
course, if both aziridine carbons are substituted the regioselectivity issue is even more 
pronounced.  
 
SCHEME 6. General mechanism for aziridine ring opening. Nucleophilic attack via either route A) or B) affords 
different regioisomers. Mixtures of the two regioisomers may be formed. 
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When TMSCN or TMSN3 are used together with TBAF to initialize the aziridine ring-opening 
reactions, high yields and high regioselectivities have been reported.70 However, nosyl-activated 
aziridines can be ring-opened directly with NaCN.71 
However, in order to avoid mixtures of regioisomers, the route in SCHEME 1 had to change 
directions. The L-amino alcohols (1a-c) were instead ditosylated to afford 5 (43-63%) by using 
two equivalents of TsCl (SCHEME 1).72 Pyridine was used as base in order to minimize the risk of 
aziridine formation. Now, no such products were obtained. 
Displacement of the OTs group in (5b) by KCN or NaCN in DMF did not result in any nitrile 
formation despite the fact that high yields of nitriles were reported in the literature.72 This could 
be due to the very low solubility of KCN in DMF. The solubility issue has also been recognized 
by others who instead used Bu4NCN in ethyl acetate to displace a mesylate.73 In our hands this 
did not give satisfying results. Likewise, the usage of Bu4NBr and NaCN to form Bu4NCN in situ 
was tested together with tosylester 5, but did not show promising results.73 Fortunately, NaCN 
dissolves readily in DMSO. Sobolewki et al. reported 65% yield when using NaCN in DMSO for 
the SN2 reaction to afford Boc-PheCH2CN.74 For the ditosylated starting material 5a-c full 
conversion was obtained when using NaCN in DMSO with gentle heating (35 ºC) which afforded 
the nitriles 6a-c (87-98%) (SCHEME 1). The obtained yield was higher than previously reported 
and no further purification was needed. 
The same conditions were used for the azide formation (3a-c) using NaN3 in DMSO (65-77%) 
(SCHEME 1). The nitriles (6a-c) were further converted to the corresponding aldehydes (7a-c) (SCHEME 
1). Not only has the reaction to be carefully handled as such, also the work-up procedure needs 
some consideration. DIBAL-H is sold as a solution in a variety of solvents (DCM, THF, or 
toluene). Often, methanol is used to quench the excess of reagents after the reaction. Methanol 
also breaks the gelatinous Al-based complexes often formed before the acidic hydrolysis to the 
product takes place. In order to isolate the product the extraction process has to be optimized. 
However, quenching the reaction with either methanol/water, citric acid or tartaric acid did not 
provide any satisfying results.75-76 With help from the author of the paper reporting a DIBAL 
reduction of the very same substrate in 85% yield, the work-up procedure was sorted out.77 
Finally, cold acetone was used for quenching the reagent and breaking the Al-complexes. 
Subsequent hydrolysis with diluted HCl gave the desired aldehydes (7a-c), although in low to 
moderate yield (22-60%) after flash chromatography. 
Since ε-protected L-lysinol is not commercially available the beginning of the route described in 
SCHEME 1 had to be modified in order to obtain the corresponding TLCK analogues. Initially, 
attempts were made to reduce the carboxylic acid moiety of ε-Cbz protected L-lysine (20) by 
LiAlH4 followed by tosylation aiming to get 22 (SCHEME 7). Instead, a by-product (23) was 
formed (SCHEME 7). Apparently, the Cbz-group had also been reduced to a methyl group due to 
the harsh conditions during the LiAlH4-reduction. Both the newly formed secondary amine and 
the primary amine became tosylated. N-Methylation from Cbz-protected precursors has been 
reported earlier. 
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SCHEME 7. The expected product 22 was not formed, instead 23 was isolated. Reagents and conditions: (i) LiAlH4, 
THF; reflux; (ii) TsCl (1 equiv.), Et3N, DMAP, DCM, rt, on. 
When lowering the temperature the reaction did not go to completion. Reduction by LiAlH4 at 0 
ºC and direct ditosylation gave too low yield. The strategy was abandoned and the focus was set 
to other alternatives. 
Textbooks in organic chemistry claim that an ester functionality needs a powerful reducing agent 
such as LiAlH4 in order to react. It is also claimed that esters are reduced by NaBH4, although so 
slowly that the reaction is not practical to use. However, several exceptions have been reported78 
and discussions of NaBH4-reductions of esters have been on-going for long.79 Accordingly, 
NaBH4 reduction of sulfonamide protected phenylalanine methyl ester was reported to give the 
corresponding alcohol in 91% yield.80 
As experienced, Cbz-groups are being labile at reducing conditions but as the Boc-group is 
known to be more stable the choice of protecting group was reconsidered. Also, the N-tosylation 
reaction was put first in the synthetic route to the TLCK analogues. The free amine in ε-Boc-
lysine methyl ester (24) was converted into sulfonamide 25 (95%) (SCHEME 8). 
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SCHEME 8. Synthetic route to TLCK analogues. (i) TsCl, Et3N, DCM, 0 C => rt, on; (ii) NaBH4, THF:ethanol, 0 
C => rt, on; (iii) TsCl, pyridine, DMAP, DCM, 0 C => rt, on; (iv) NaN3 (2 equiv.), DMSO, rt, on; (v) NaCN (2 
equiv.), DMSO, 35 C, on; (vi) 1) DIBAL-H in toluene, THF, -65 C, 45 min., 2) dilute aq. HCl; (vii) TFA/DCM, rt, 
60-90 min. 
Then the methyl ester was reduced by NaBH4 to afford alcohol 26 (94%). Subsequent O-
tosylation of 26 afforded the ditosylated derivative 27 (37%). Again, pyridine was needed as the 
base in order to avoid aziridine formation. The ditosylated derivative (27) could now be used in 
the same manner as described for the synthesis of the TPCK analogues, i.e. the OTs-group was 
expelled by either NaN3 or NaCN to give azide 28 or nitrile 29, respectively. The nitrile (29) was 
further converted via DIBAL-H reduction and acidic hydrolysis to aldehyde 30. The Boc-
protecting group of 26, 28, and 29 was removed by TFA/DCM to afford 31, 32 and 33, 
respectively. 
 
SCHEME 9. Unfortunately, attempts to reach aldehydes 34a and 34b were not successful. 
Additionally, some attempts were also made to synthesize the L-amino aldehydes (34a, 34b) 
(SCHEME 9). However, gentle oxidation of N-Ts protected L-amino alcohol by either Dess-Martin 
periodinane, or Swern oxidation did not show satisfying results. Although such aldehydes are 
known in the literature either as starting materials or intermediates, they are not used as final 
products. Moreover, the nucleophilic properties of the sulfonamide have been shown to cause 
unexpected reactions and formation of dimers.81 The Dess-Martin protocol showed conversion of 
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the starting material but the product could not be isolated in the high purity requested for 
compounds used in biological assays. Due to the acidic properties of the sulfonamide the 
intermediate did not react as expected and by-products were obtained. 
In these highly convergent synthetic routes several TPCK/TLCK analogues were synthesized, 
which were tested for inhibition capacity, further discussed in the evaluation chapter. 
 
4.2 SYNTHESIS OF PIPERIDINE ANALOGUES (PAPER II and III) 
This chapter is divided into five sections, starting with formation of the new stereogenic centre by 
reductive amination, via a study of stereoselectivity in such reductive aminations followed by 
calculations of conformational distributions, and finally the synthesis of the piperidine-based 
analogues. 
4.2.1 Reductive amination-formation of new stereogenic centre 
Peptide synthesis is inevitably a sequence of repetitive processes, so is also the synthesis of the 
di-, tri- and tetrapeptide analogues of LLGG and LGGP in this thesis (FIGURE 21). The sequence 
starts with connecting the piperidine moiety to the amino acid that follows Gly236 or Gly237 in the 
IgG sequence (either glycine or proline), and thereby a new stereogenic centre is formed. 
Thereafter, the pip236G moiety is coupled to L-proline C-terminally. Finally, the N-terminal L-
amino acids are coupled. 
 
FIGURE 21. The schematic route for synthesis of peptide analogues. By forming the stereogenic center in the first 
reaction, the absolute configurations in all the following compounds will be known, provided that no racemization 
occurs.  
 
 
Reductive amination between Boc-protected 3-piperidone 35 and ethyl glycinate 36 was used to 
synthesize the pip236Gly-fragment of the peptide analogues. The unsymmetrical ketone is 
prochiral and upon imine formation and subsequent reduction a stereogenic centre is formed and 
the racemic product (rac)-37 was collected (76%) (SCHEME 10).  
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SCHEME 10. Synthesis of pip236G. Reagents and conditions: (i) NABH(OAc)3, AcOH, DCM, rt, on. 
The pip236Gly-fragment can also be synthesized by reductive amination using interchanged 
functionalities of the starting materials. The stereogenic centre is unchanged while amine (R)-38 
reacts with ethyl glyoxylate (39) to form (R)-37 with an enantiomeric ratio (er) of 95:5 (SCHEME 
10). The enantiomer (S)-37 was also synthesized, with a somewhat lower er 7:93 (SCHEME 10). 
The reason for not obtaining enantiomerically pure products in these reactions might be due to 
not strictly enantiopure starting materials. The ratio was considered to be too low to be useful for 
synthesis of the piperidine-based inhibitors. However, the two enantiomers synthesized from the  
3-piperidone (35) could be identified by the samples from the reactions starting from the 3-
aminopiperidine ((R)- and (S)-38) and comparison of the retention times from HPLC (chiralpak 
AD) analysis, so called chemical correlation. 
Reductive amination is the reaction between either ammonia, a primary or a secondary amine and 
a ketone or an aldehyde to form primary, secondary or tertiary amines via an imine intermediate 
which is seldom isolated.82 The reaction is a two-step process in which the nitrogen of the amine 
attacks the carbonyl carbon and water is expelled to form an imine (either aldimine or ketimine) 
which is subsequently reduced to afford the product.  
Also for the Gpip237 analogues the formation of the new stereogenic center is the first step in the 
route. The reductive amination between 35 and L-proline amide 40 affords 41 with a 
diastereomeric ratio (dr) of 59:41 (68%) (SCHEME 11). When a secondary amine reacts with a 
ketone and water is expelled the formed intermediate is a tertiary iminium salt. The iminium salt 
may eventually be deprotonated to form the more stable enamine. However, enamines are not 
reduced by the hydrides used for reductive aminations, as the following example shows. 
 
SCHEME 11. Synthesis of pip237P leading to Gpip237 analogues. Reagents and conditions: (i) NaBH(OAc)3, AcOH, 
DCM, rt, on.  
The double bond electrons in enamine 44 is prevented to migrate to the nitrogen as the nitrogen is 
already fully substituted (SCHEME 12). The enamine was not reduced to the corresponding 
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saturated cyclohexyl derivative by a traditional hydride reagent, L-selectride (LiBH(sec-
butyl)3).83 Enamine formation is usually suppressed in an acidic environment. 
 
 
SCHEME 12. Literature example showing evidence for non-reducible enamines. The enamine is unable to rearrange 
into the corresponding iminium ion needed for the reduction. LiBH(sec-butyl)3 was used as the reducing agent.83  
4.2.2 Study of stereoselective reductive aminations (PAPER II)  
Stereoselectivity is applicable for reactions when two stereoisomers are formed and one of the 
two is favoured. An iminium salt (45) structurally similar to the intermediate 42 shown in 
SCHEME 11, but now derived from asymmetric 3-methylcyclohexanone and symmetric pyrrolidine 
is attacked by NaBH3CN to form 46:47 in a ratio of 74:26, favouring equatorial attack and hence 
the axial amine (86%) SCHEME 13.83 For comparison of structures and ratios, some more 
examples are shown. 
 
SCHEME 13. Literature example of diastereomers formed in a reductive amination using NaBH3CN as reducing 
agent.83A hydride attack from the equatorial direction forms the axial amine, whereas when the hydride attack comes 
from the axial direction the equatorial amine is formed. 
Reports of asymmetric synthesis to afford both natural and new amino acids are extensive in the 
literature, but the use of amino acid esters as starting materials in a reductive amination is sparse. 
However, an example of reductive amination using an oxo-proline derivative (48) which directs 
the hydride attack (NaBH3CN) of the intermediate imine to the opposite side of the t-butyl ester 
moiety, the reaction results in a dr of 87:13 of (SS)-50:(RS)-50 (SCHEME 14).84 
 
SCHEME 14. Literature examples of reductive amination with NaBH3CN starting from amino acid esters.84  
The two examples shown are similar to ours, yet different. The ratios shown are higher, how can 
we improve the ratio? The reaction shown in SCHEME 11 needs some more detailed consideration 
and can be redrawn (CHART 1). When both starting materials are asymmetric the stereoselectivity 
issue becomes more complex. The intermediates form either Z- or E-isomers of the iminium 
salt.85 The impact of the stereogenic centre in the amino acid is different for the two isomers. 
When such a substituent is large enough it might constitute a steric hindrance for the approaching 
reducing agent. Both Z- and E-isomers can afford the RS- and SS-diastereomers when the new 
stereogenic centre is formed. The stereogenic centre of the L-amino acid ester moiety is 
unaffected and keeps the S-configuration.  
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CHART 1. Z- and E-isomer 42 as intermediates in reductive amination towards 41. 
What can we do to drive the equilibrium in any direction? For a cyclohexane-based system one 
methyl group can in fact alter the position of the equilibrium. There are two possible chair 
conformations of methylcyclohexane (51) with the substituent either in an axial or equatorial 
position (FIGURE 22A). The energy difference between the two conformers is 7.2 kJ/mol, which 
corresponds to a ratio of 95:5, favoring the conformation with an equatorial methyl substituent. 
O
91:9
5.7 kJ/mol
95:5
7.2 kJ/mol
23.0 kJ/mol
99.99:0.01
A
B
C
O
51eq 51ax
52eq 52ax
53eq 53ax
 
FIGURE 22A-C. Cyclohexane-based conformations with energy differences and isomeric ratios. In all examples the 
equatorially substituted conformer is favored (shown to the left). 
The two methyl groups in cis-1,3-dimethylcyclohexane force the ring to adopt the conformation 
with both groups equatorially positioned (FIGURE 22B). In 3-methylcyclohexanone (53), the 
energy difference is much smaller, and close to that for the equilibrium of 51eq:51ax, the ratio is 
91:9 still in favor of the conformation with an equatorially positioned substituent (FIGURE 22C). 
The 1,3-diaxial interaction is less pronounced in 53ax compared to the disubstituted cyclohexane 
(52ax) as the carbonyl group is directed outwards from the ring.  
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FIGURE 23. Pyramidal and ring inversion of piperidine.86 
As cyclohexane, piperidine also adopts the characteristic chair conformation and ring inversion 
occurs. The bond angles are similar in both rings but the C-N bond is somewhat shorter and the 
chair conformations of piperidine are somewhat more puckered than for cyclohexane. In contrast 
to cyclohexane, piperidine has two distinct chair conformations as pyramidal inversion of the 
nitrogen occurs (FIGURE 23). However, the pyramidal inversion is very fast. For separate 
detection of the two isomers (= invertomers) NMR studies have been performed at temperatures 
as low as -174 ºC.86 However, the ring inversion is slower and detectable already at -100 ºC.  
Although not being a reductive amination, 35 and enantiopure phenylethanamine 55 reacted with 
trialkyl phosphite (P(OEt)3) affording a dr of 40:60 (SCHEME 15).87 In fact, the intermediate is 
similar to the iminium ions seen earlier but the hydride is exchanged for a nucleophilic phosphite 
reagent. 
 
SCHEME 15. Literature example of a reaction with similar intermediate as obtained in the reductive aminations 
used in this thesis. Reagents and conditions: P(OEt)3, AcOH, EtOH, 50 ºC.87 
What is the origin of the observed stereoselectivity? Could the presence of a stereogenic centre in 
the intermediate affect the stereochemical outcome of the reaction? Could the stereoselectivity be 
improved? To answer such questions a study of the stereoselective outcome in the piperidone-
amino acids system was undertaken. 
In order to evaluate the possibilities to control the stereoselectivity using unsubstituted N-
protected 3-piperidone and L-amino acid esters a study of the stereoselectivity in reductive 
aminations was undertaken. The following four parameters were varied; the N-protecting group, 
the amino acid, its ester moiety and the reducing reagent (FIGURE 24). 
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FIGURE 24. In the schematic reductive amination four parameters were evaluated regarding to their influence on 
the dr of the products. 
The N-protecting group used was either Boc or trityl (Tr) which are different in features such as 
flexibility, size, compactness and hybridization. The amino acids alanine, valine, phenylalanine 
and proline were chosen to represent differences in size and rigidness. Methyl and t-butyl esters 
were used as they have different bulkiness. Six different borohydride reagents, derived from 
NaBH4 and increasingly bulky carboxylic acids, were first evaluated as reducing agents, two of 
them were then used for further evaluations. Thus, the chosen parameters are not affecting the 
structure of the final unprotected product, except for the specific amino acid used. As the 
diastereomers did not separate on silica gel, they were analyzed by HPLC equipped with a 
column containing a chiral stationary phase (Chiralpak AD). In this thesis, the diastereomeric 
ratio (dr) is always reported in the order as the peaks eluted. The dr obtained is a measurement of 
the stereoselectivity, 50:50 means no favoured diastereomer. 
The six different borohydride-based reducing agents were evaluated in the reductive amination of 
Boc-protected 3-piperidone (35) and valine methyl ester (58) (TABLE 1). The reagents in TABLE 1, 
Entries 3-6, were prepared in situ from NaBH4 and the listed carboxylic acids and were used 
according to the general protocol for direct reductive aminations. All reducing agents but 
NaBH3CN gave yields above 70%. In addition, all reducing agents derived from acyclic 
carboxylic acids, showed low or no stereoselectivity. For further reactions, NaBH(OAc)3 and 
NaBH(O-2-ethylhexanoyl)3 were chosen. 
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TABLE 1. Influence of reducing reagent on yield and dra 
 
Entry reagent or R yieldb drc 
1 NaBH(OAc)3 85 48 : 52 
2 NaBH3CN+AcOH 43 39 : 61 
3 
 
78 50 : 50 
4 
 
72 50 : 50 
5 
 
71 56 : 44 
6 
 
72 59 : 41 
aReactions were carried out with N-Boc-3-piperidone (1.0 equiv.), L-valine methyl ester (1.0 equiv.), mol. sieves and 
the listed reducing reagents (1.0 equiv.) in DCM at rt overnight. The reducing reagents were either used as such or 
formed in situ from NaBH4 (1 equiv.) and the listed carboxylic acids (3.5 equiv.) in DCM at rt overnight; bIsolated 
yields (%); cThe ratio reflects the elution order of the diastereomers from HPLC (Chiralpak AD) analysis. 
Results such as yields and dr from reductive aminations performed using small and large 
reducing reagents when exploring the effects of different protecting groups on piperidone and of 
side chains and ester groups of different amino acids are shown in TABLE 2. Also the absolute 
configuration of the product is reported when known (for determination of absolute 
stereochemistry, see Appendix 1). The dr is reflecting the elution order from the HPLC 
(Chiralpak AD), and care must be taken when comparing different data. For example, the 
diastereomers of methyl and t-butyl esters of the same amino acid are not necessarily eluting in 
the same order. When the absolute stereochemistry is known, the reported ratio is still reflecting 
the elution order from the HPLC (Chiralpak AD). Also for the proline derivatives the elution 
order was reversed when the N-protecting group changed from Boc to trityl. 
 
 
 
33 
 
TABLE 2. Influence of protecting groups, L-amino acid esters and reducing reagents on yield 
and dra 
 
   Pg = Boc Pg = Tr 
Entry L-aa ester reagentb yield / drc / config d yield / drc / config d 
1 AlaOMe A 62/44:56/ - - 
2 AlaOMe B 38/49:51/ - - 
3 AlaOtBu A 30/56:44/SS:RS  
4 AlaOtBu B 78/52:48/SS:RS  
5 AlaOtBu A  61/50:50/ - 
6 AlaOtBu B  45/56:44/ - 
7 ValOMe A 85/48:52/ -  
8 ValOMe B 71/56:44/ -  
9 ValOMe A  67/55:45/ - 
10 ValOMe B  69/39:61/ - 
11 ValOtBu A  49/53:47e/ - 
12 ValOtBu B  44/36:64e/ - 
13 PheOMe A  62/61:39/ - 
14 PheOMe B  53/41:59/ - 
15 ProOMe A 74/59:41/RS:SS  
16 ProOMe B 74/62:38/RS:SS  
17 ProOMe A  47/38:62/SS:RS 
18 ProOMe B  55/21:79f/SS:RS 
19 ProOMe C  52/50:50/SS:RS 
20 ProOMe D  15/20:80/SS:RS 
21 ProNH2 A 68/59:41/RS:SS  
 aReactions were carried out with N-protected 3-piperidone (1.0 equiv.), the listed L-amino acid esters (1.0 equiv.), 
molecular sieves and reducing reagents (1.0 equiv.) in DCM at rt overnight. The reducing reagents were either used 
as such or formed in situ from NaBH4 (1.0 equiv.) and 2-ethyl hexanoic acid (3.5 equiv.) in DCM at rt overnight; 
bReagent A = (NaBH(OAc)3, Reagent B = NaBH(O-2-ethylhexanoyl)3, Reagent C = NaCNBH3 + AcOH, Reagent D 
= NaBH(O-N-acetyl-prolinoyl)3; cIsolated yields (%) with dr based on the elution order from HPLC (Chiralpak AD); 
dAbsolute configuration as determined by X-ray crystallography (Ala) or chemical correlation (Pro); edr is 
calculated from the two peaks representing each OtBu-group of the diastereomers in the 1H NMR spectrum of the 
product mixture;fThe reaction has been carried out in triplicate (dr = 19:81, 20:80, 24:76). 
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Six reactions using alanine methyl or t-butyl esters showed a large variation in yields (30-78%) 
and virtually no stereoselectivity (TABLE 2, Entries 1-6). Neither the bulk of the larger ester moiety 
(t-butyl), the bulk of the larger reducing reagent (B) nor the bulk of the larger N-protecting group 
(Tr) could affect the stereoselectivity compared to the smaller substituents used. The results for 
the valine-based reactions showed also a fairly large variation in the yields (44-85%) (TABLE 2, 
Entries 7-12). The reactions performed with Boc-protected 3-piperidone showed no 
stereoselectivity (TABLE 2, Entries 7-8). However, by using trityl and the larger reducing agent (B) 
the stereoselectivity increased for both the methyl and t-butyl esters to 39:61 and 36:64, 
respectively (TABLE 2, Entries 9-12). As the ratio was close to 50:50 when using the smaller 
reducing reagent, the increased stereoselectivity is mainly a consequence of the size of the 
reducing reagent. The yields in the reactions with Tr-3-piperidone and phenylalanine esters are 
53-62% (TABLE 2, Entries 13 and 14). Interestingly, the diastereomeric ratio (~60:40) is inverted 
when the reducing reagent is changed. When using proline esters, the results become more 
interesting (TABLE 2, Entries 15-21). Firstly, the RS-diastereomer is nearly always formed in excess 
(N.B. the elution order from the HPLC (Chiralpak AD) changes with the protecting group). Using 
either the proline ester or amide did not affect the stereoselectivity as the ratios were the same 
(59:41), both favoring the RS-diastereomer (TABLE 2, Entries 15 and 21). Neither did the size of the 
reducing reagent affect the ratio (TABLE 2, Entries 15 and 16). However, when the largest protecting 
group is used together with the large reducing reagent (B) the ratio increases to 21:79, still 
favoring the RS-diastereomer. Interestingly, when using an even larger reducing reagent (D), the 
ratio does not increase, instead the yield drops to 15% (TABLE 2, Entry 20). This can indicate that 
the ratio cannot be improved further and this is the highest dr possible to obtain in the 3-
piperidone-amino acid system. 
To conclude, in the reductive aminations performed with N-protected 3-piperidone and alanine 
esters none stereoselectivity could be observed. Most probably, the side chain of alanine is too 
small to affect the stereoselectivity, even a large N-trityl protecting group, the t-butyl ester or a 
large reducing reagent ((±)-2-ethylhexanoyl) cannot compensate for the small methyl side chain 
of alanine. When the side chain is increased, as for valine, and the large reducing reagent is used 
the stereoselectivity can be affected to some extent giving a dr of about 40:60. For the even larger 
but more flexible side chain of phenylalanine such combinations are not needed, the ratio is in the 
60:40 range also when using a smaller reducing agent (NaBH(OAc)3). This implies that an 
increased ratio would be possible to obtain when using a larger N-protecting group. However, for 
the most bulky amino acid, proline, the stereoselectivity is not further increased (from 60:40) 
until both the larger protecting group and the larger reducing reagent are combined, providing the 
highest ratio (21:79) obtained in this study.  
 
4.2.3 Calculation of conformational distributions 
Conformations matter. For example, often an enzyme inhibitor has to change its spatial 
arrangement from the most stable conformation (the global minimum) in order to bind with 
optimal complementarity to the active site of an enzyme. If the change of conformation means a 
large deviation in energy from the global minimum it is unlikely that the binding will be strong. 
The limit of such deviation has been suggested to be 12 kJ/mol in order to secure a strong affinity 
between the inhibitor and the enzyme.88 In fact, if the energy of two conformations differ by12 
kJ/mol, the higher energy level is populated by less than 1% of the molecules, the rest adopt the 
global minimum conformation. A theoretical example of Boltzmann distributions of seven 
conformations is seen in TABLE 3. Seven energy levels Ni, each increased +2 kJ/mol from the 
previous more stable level, were used to calculate the Boltzmann distribution (%) of the 
conformers occupying those energy levels (Eq. 1 and 2). Of course, the global minimum is always 
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the most populated level and as seen, the populations decrease as the energy increases for the 
higher levels. 
Ni+1/Ni = e–E/RT   Eq. 1 
i Ni = N    Eq. 2 
TABLE 3. Example of Boltzmann distribution in per cent for a pre-chosen set of seven energy levels, 
increased by + 2kJ/mol intervals.a 
Ni  ΔE (kJ/mol) distribution (%) 
N0  0 55.6 
N1  2 24.8 
N2  4 11.1 
N3  6 4.9 
N4  8 2.2 
N5  10 1.0 
N6  12 0.4 
   Σ 100% 
aEquation 1 was calculated with R = 8.314 J/mol/K and T = 298 K. 
Since most of the reductive aminations performed with N-protected 3-piperidone in this thesis 
show diastereomeric ratios of either 40:60 or 60:40, we wanted to investigate the preferred 
conformations of the intermediates in more detail to try to understand the origin of the 
stereoselectivity and also possibly predict the direction of attack by the reducing reagent. 
Conformational searches were performed individually on the Z- and E-imine intermediates 
formed in the synthesis of 68, 63 and 62 (68i, 63i, and 62i, respectively) using the MacroModel 
program and the OPLS2005 force field.49 Only 11 conformers were found for each isomer of 68i 
when trityl was used as the protecting group, compared to the Boc-protected isomers which gave 
up to 30 conformers each. All conformers, within 12 kJ/mol from the global minimum, were 
visually inspected and divided into the Z1, Z2, E3 or E4 chair conformations as depicted in 
FIGURE 25.  
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FIGURE 25. Chair conformations of Z- and E-imines (row II) as intermediates. The intermediates can be attacked 
axially (Hax, row III) or equatorially (Heq, row IV) to afford the R- and S-configuration at the new stereogenic center. 
For both Z- and E-isomers two chair conformations are possible (row II) and those can either be 
attacked from the axial direction (products shown in row III, Hax) or from the equatorial direction 
(products shown in row IV as Heq). The stereoselective outcome is a delicate issue of equilibria. 
For instance, hydride attack from the axial direction on Z1- and E3-isomers affords products with 
S- and R-configuration, respectively. Thus, the position of the equilibrium of the Z- and E-
isomers becomes important in order to get a high stereoselectivity. Moreover, an axial attack on 
the Z1- and Z2-isomers also affords products with S- and R-configurations, respectively. 
Therefore the position of the equilibrium of Z1 and Z2 also becomes important for a high 
stereoselectivity. Stabilization of one of all possible chair conformations (or destabilization of the 
others) may enhance the stereoselectivity towards one of the diastereomers.  
From now on, the pre-existing stereogenic centre will be omitted for clarity. The reduction of the 
Z- and E-imines must be governed by the possibility of a ring inversion in piperidine and by the 
fact that the hydride reagents can approach from either the axial or equatorial direction, or both.  
From the conformational search, the structures of the most stable chair conformation of the Z1-, 
Z2-, E3- and E4-isomers of 68i were obtained (FIGURE 26). The Z2-68i isomer is the most stable, 
but the relative energies between the isomers are very close. 
 
FIGURE 26. The most stable chair conformation of the Z1-, Z2-, E3- and E4-isomers of 68i. 
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With the relative populations in hand, and by assuming an axial attack of the hydride, summing 
up the percentages of Z1 and E4 conformers, both leading to the S-configuration of the product 
after an axial attack, and Z2 and E3 conformers, affording the R-configuration of the products, the 
calculated ratio could be obtained.  
At this stage it became inevitable to know the absolute stereochemistry of the formed products, 
for enabling comparison of calculated and experimental derived ratios and such process was 
undertaken (see Appendix 1 for determination of the absolute configuration). The results from the 
determination showed that the diastereomer formed in excess had the R-configuration at the 
newly formed stereogenic centre for both proline derivatives 68 and 63. Compound 62 showed no 
stereoselectivity. 
Now the comparison could be made, the conformational search based calculated ratios of the 
imine intermediates are close to the experimentally derived ratios of the product (TABLE 4). In 
Entry 1, for 68 the calculated ratio 25:75 is close to the experimental ratio 21:79. When equatorial 
attack is assumed in the calculation, the ratio is the same but inverted. 
Table 4. Experimental and calculated dr based on Boltzmann distribution analysis of the Z- and E-isomers of 
68, 63 and 62 assuming axial attack by the reducing agent (NaBH(O-2-ethylhexanoyl)3).a 
Entry productb 
experimental 
NaBH(OEh)3 
calculated 
only ax attack 
calculated 
ax at Z1 and Z2 
calculated 
ax at E3 and E4 
1 
2 
SS-68/RS-68 
RS-63/SS-63 
21:79 
62:38 
25:75 
66:34 
20:80 
65:35 
32:68 
68:32 
3 SS-62/RS-62 52:48 60:40 73:27 32:68 
aCalculations assuming equatorial attack by the reducing agent result in reversed ratios. For example, SS-68/RS-68 
show a calculated dr = 75:25 when all Z- and E-isomers of 68i are attacked from the equatorial direction.  
However, by a closer inspection of the conformers in FIGURE 26, the reaction site in the E3- 
conformer is sterically hindered from the axial direction by both the trityl and ester groups. It 
seems impossible for a large reducing reagent to reach the trigonal carbon of the imine. 
Therefore, the E3-conformer was removed from the calculations and the calculated ratio became 
36:64, still favoring the RS-diastereomer. However, if both E-conformers are removed, and the 
calculation was performed with only the Z-conformers a ratio of 20:80 was obtained, with the RS-
diastereomer in excess. This is exactly the ratio as seen experimentally for 68. In fact, all the 
calculations are close to the experimental ratio and all show that the RS-diastereomer prevails 
with the assumption of an axial attack by the reducing reagent. 
For 68i, the calculated ratios are similar in all cases and also similar to the experimental ratio, the 
RS-diastereomer prevails and an axial attack by the reducing reagent seems likely. For 62, the 
calculated ratio implies that a stereoselective outcome would be likely, but different isomers 
prevail. However, the experimentally derived ratio did not indicate any stereoselectivity. 
In the literature, correlation between conformation and reactivity is discussed.89 The Curtin-
Hammett principle says that the product distribution is solely correlated to the energy barrier of 
the two transition states, and an isomeric equilibrium process is said to be fast. However, 
Winstein/Holness and Eliel/Ro correlate the product distribution to relative reaction constants 
irrespective of the equilibrium rate. In the schematic reaction in FIGURE 27, A2 and A3 represent 
the conformers interconverting in an equilibrium fashion, and A1 and A4 are the products.90  
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FIGURE 27. Energy diagram of the schematic reactions of two conformers (A2, A3) related by an equilibrium 
process, which form different products (A1, A4) according to the A) Curtin-Hammett Principle and B) the 
Winstein/Holness hypothesis. The energy levels are arbitrary. 
In the first case, the reactions to A1 and A4 are slower than the equilibrium process, i.e. k21, k34 
<< k23, k32, the reactions follow the line in FIGURE 27A and the so-called Curtin-Hammett 
principle is said to hold. The ratio of the products (A1:A4) will be determined by the formation 
rates, that is the difference in their two transition states TS21 and TS34. In the second case (FIGURE 
27B) the equilibrium process is slower than the reactions to A1 and A4, i.e. k23, k32 << k21, k34. 
This means that the product ratio (A1:A4) is determined by the ratio of the conformers of the 
starting material which is the relative populations of A2 and A3.  
As seen above, the relative populations can be derived from conformational analysis of the 
starting materials followed by calculation of the Boltzmann distribution. 
By transferring the schematic picture in FIGURE 27 to the reductive step of Z and E-imines 
presented in FIGURE 25, the starting materials A2 and A3 can be represented by either the Z- or E-
chair conformations. A1 and A4 represent the products, the R- and S-isomers.  
Since the calculated ratios are in accordance with the experimental data, diastereomeric ratios 
may be predicted as described above with the assumptions made and the reaction follows the 
non-Curtin Hammett principle. However, no TS-calculations have been made in this thesis. The 
energy gap between the two starting materials could be exactly the same as the energy-gap 
between the two TS shown in FIGURE 27B. Two conclusions may be drawn: Since the calculated 
data predict the correct major diastereomer of the products, the assumption that the attack occurs 
from the axial direction is correct. Since the highest calculated ratio is 25:75, this seems to be the 
top limit for the stereoselectivity in the N-protected 3-piperidone L-proline system.  
In the literature, discussions on the issue of stereoselectivity provide examples of borohydride 
reduction of either the keto function of piperidone or the imine function of cyclohexane 
derivatives but not on systems similar to those used in this thesis. Commonly, ketones are 
attacked from the equatorial side when using large reducing agents but imines are attacked from 
the axial direction.83 In nucleophilic addition to a trigonal carbon steric hindrance and electronic 
effects are usually responsible for the stereochemical outcome. When the trigonal carbon is part 
of an imine the steric hindrance is increased by one or two substituents on the nitrogen. 
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According to Cieplak the direction of the nucleophilic attack is favoured by an antiperiplanar 
geometry in relation to a neighboring C-H bond over C-C or C-N bonds, which in a sixmembered 
heterocyclic system means from the axial direction.91  
 
4.2.4 Synthesis of piperidine-based analogues (PAPER III) 
The synthetic route to the peptide analogues continued. As discussed in the previous sections, the 
enantiomers of 37 and the diastereomers of 41 could not be synthesized in a stereochemical pure 
fashion. Instead, the isomers were separated by preparative HPLC using an enantioselective 
stationary phase (Chiralpak AD). For example, two grams of (rac)-37 was separated into (R)- and 
(S)-37 in 11 injections to afford sufficient amount for the synthetic route to follow. With 
enantiopure starting materials the synthesis towards the peptide analogues could be started, the 
stereochemical integrity was kept under control throughout the whole reaction sequence. No 
racemization or epimerization were observed after any of the amino acid coupling reactions. 
The synthetic routes to the di-, tri- and tetrapeptide analogues are outlined in SCHEME 16. 
Aminolysis of the isolated (R)- and (S)-37 with ammonia in methanol afforded the amides (R)- 
and (S)-69. Acidic cleavage of the Boc protecting group mediated by TFA/DCM gave (R)- and 
(S)-74 (pip236G) in quantitative yields.  
 
SCHEME 16. Route to the piperidine analogues (R)-, (S)-pipG (70), the tripeptide analogues (R)-, (S)-LpipG (74) 
and the tetrapeptide analogues (R)-, (S)-LLpipG (77). Reagents and conditions: (i) NH3/MeOH, rt, 72 h; (ii) TFA, rt, 
12 h; (iii) Cbz-OSu, Et3N, DCM, 0 °C => rt, 17 h; (iv) 1) TFA, rt, 16 h, 2) Boc-L-Leu x H2O, EDC, HOBt, DCM, 
molecular sieves, Et3N, rt, 15 h; (v) NH3/MeOH, rt, 72 h; (vi) 1) H2, Pd/C, ethanol, rt, 72 h, 2) TFA/DCM, rt, 4 h; 
(vii) 1) TFA/DCM, rt, 16 h, 2) Boc-L-Leu x H2O, EDC, HOBt, DCM, molecular sieves, Et3N, rt, 15 h; (viii) 
NH3/MeOH, rt, 168 h; (ix) 1) H2, Pd/C, EtOH, 3 h, 2) TFA/DCM, rt, 14 h.  
Furthermore, the isolated enantiomers (R)- and (S)-37 were protected using Cbz-succinimide to 
afford (R)- and (S)-71. The Cbz-group was used, for its complementary stability during Boc-
deprotections performed in later synthetic steps. The enantiomers (R)- and (S)-71 were Boc-
deprotected followed by coupling with Boc-L-leucine to afford (R)- and (S)-72. All couplings 
were mediated by EDC and HOBt, to pre-activate the carboxylic acid in order to react with the 
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nucleophilic amines.92-93 Aminolysis afforded amides (R)- and (S)-73, which were deprotected to 
give (R)- and (S)-74 (Lpip236G), respectively. Boc-deprotection of (R)- and (S)-72 and subsequent 
coupling to Boc-L-leucine gave (R)- and (S)-75, respectively. Aminolysis afforded (R)- and (S)-
76. Finally, the Cbz- and Boc-protecting groups were removed by catalytic hydrogenation (Pd/C) 
and TFA cleavage, respectively, to afford (R)- and (S)-77 (LLpip236G). The total yield for the 
synthesis of (R)- and (S)-76 over eight steps from (R)- and (S)-37, respectively, was 37 and 48%.  
Attempts to synthesize dipeptide analogues such as pipA, pipV and pipF starting from the 
compounds obtained in the reductive amination study were made. Aminolysis of (rac)-61 gave 
(rac)-78 in 55% (SCHEME 17). Neither (rac)-59 nor (rac)-77 reacted with ammonia in methanol. 
Efforts to prolong the reaction times or using microwave-assisted heating were made but without 
detection of products, only unreacted starting material remained. Compound (rac)-78 was 
deprotected to afford (rac)-81 (quant. yield). 
 
SCHEME 17. Attempts to synthesize dipeptide analogues such as pipA, pipV and pipF. Reagents and conditions for 
synthesis of 81: (i) NH3 in methanol, rt, 72 h; ii) TFA/DCM, rt, on.  
The synthetic sequence to the tri- and tetrapeptide analogues pip236GP (84) and Lpip236GP (86) is 
shown in SCHEME 18. Ester hydrolysis of the Cbz-protected (R)-and (S)-71 (from SCHEME 16) 
afforded the carboxylic acid derivatives (R)- and (S)-82 (95 and 99%) and subsequent coupling to 
L-proline amide gave (R)- and (S)-83, respectively. Compounds (R)- and (S)-83 was Boc-
deprotected (TFA/DCM) to provide a small portion of (R)- and (S)-84 (pip236GP) and the rest was 
coupled with Boc-L-leucine mediated by HOBt and EDC to give the epimers (R)- and (S)-85.  
 
SCHEME 18. Route to the tripeptide analogues pipGP (84) and the tetrapeptide analogues LpipGP (86). Reagents 
and conditions: (i) LiOH 1M aq, THF/MeOH/H2O 3:1:1, 0 °C 30 min, rt, 3 h; (ii) L-ProNH2, EDC, HOBt, Et3N, 
DCM, rt, 16 h; (iii) 1) H2, Pd/C, EtOH, rt, 24 h, 2) TFA/DCM, rt, 4 h; (iv) 1) TFA, rt, 16 h, 2) Boc-L-Leu x H2O, 
EDC, HOBt, DCM, molecular sieves, Et3N, rt, 15 h; (v) 1) H2, Pd/C, EtOH, rt, 48 and 24 h, 2) TFA/DCM, rt, 4 h. 
Finally, the Cbz- and Boc-groups were removed as described above to give (R)- and (S)-86 
(Lpip236GP). The total yield for the synthesis of (R)- and (S)-86 over seven steps was 29 and 
43%, respectively. The 1H NMR spectrum of (R)-85 showed five doublets assigned to the two 
methyl groups in the leucine side chain which implies that the molecule adopts several different 
conformations at room temperature. After the deprotection, the 1H NMR spectrum of both (R)- 
and (S)-86 showed two doublets assigned to the two non-equivalent methyl groups, as expected.  
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The synthesis route of the tri- and tetrapeptide analogues 89 and 90 (Gpip237P, LGpip237P) in 
which the piperidine moiety replaces Gly237 in the IgG sequence started by separation of (rac)-41 
by preparative HPLC (Chiralpak AD) to give (R)- and (S)-41 (SCHEME 19). (The absolute 
configurations were determined, see Appendix 1). Diastereomers (R)- and (S)-41 were Boc-
deprotected by TFA/DCM and the free amines were coupled to EDC/HOBt-activated Boc-
protected glycine to afford (R)- and (S)-87. Deprotection with TFA/DCM gave (R)- and (S)-88 
(Gpip237P) as TFA salts. Another portions of (R)- and (S)-87 were coupled with Boc-protected L-
leucine to afford (R)- and (S)-89 and subsequent deprotection with TFA/DCM afforded (R)- and 
(S)-90 (LGpip237P).  
 
SCHEME 19. Route to the tripeptide and the tetrapeptide analogues (R)-, (S)-Gpip237P (89) and (R)-, (S)-LGpip237P 
(90). Reagents and conditions: (i) 1) L-Pro-NH2, NaBH(OAc)3, HOAc, DCM, rt, 20 h, 2) preparative HPLC 
(Chiralpak AD); (ii) 1) TFA/DCM, rt, 2) Boc-Gly, EDC, HOBt, DCM, 0 oC  rt, 15 h; (iii) TFA/DCM, rt, 20 h; (iv) 
1) TFA/DCM, rt, 20 h, 2) Boc-L-Leu, EDC, HOBt, Et3N, DCM, 0 oC => rt, 15 h; (v) TFA/DCM, rt, 12 h. 
In some instances the removal of Cbz-group resulted in N-ethylation. For example, N-ethylated 
by-products were formed during the Cbz-deprotection of (R)- and (S)-73 using catalytic 
hydrogenation (Pd/C 10%) in ethanol. Isolation of the by-products after prolonged reaction time 
and subsequent TFA hydrolysis gave LLpip236EtG analogues (R)- and (S)-93 (SCHEME 20). N-
Ethylated by-products were also isolated in the deprotection of (R)- and (S)-71 (not shown). 
 
SCHEME 20. N-Ethylated by-products were isolated during Cbz-deprotection. Reagents and conditions: (i) H2, 
Pd/C, EtOH, rt, 144 h (23 and 13%), ii) TFA/DCM, rt, 16 h (99 and 98%). 
Already after three hours reaction time by-product formation was observed. To verify the 
structure, isolated Cbz-deprotected (R)-91 was converted to the corresponding ethylated product 
(92) in 76% yield via reductive amination using acetaldehyde and NaBH(OAc)3 (SCHEME 20). 
The NMR spectra of the synthesized compound and that of (R)-92 were identical. It has been 
proposed that a Pd-catalyzed oxidation of ethanol to acetaldehyde can occur during the 
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hydrogenation reaction.94-95 The acetaldehyde forms an imine with the secondary amine in 91, 
and a subsequent reduction provides the ethylated by-product (SCHEME 20). 
Synthesized compounds were screened for inhibition capacity, which is further discussed in the 
evaluation chapter. 
 
4.3 SYNTHESIS of BICYCLIC DERIVATIVES 
Initially, efforts were put into synthesizing the enaminone-based bicyclic scaffold shown in 
FIGURE 28A.  An enaminone contains the conjugated system N-C=C-C=O.96  Starting from N-
protected 3,5-dioxopiperidine, three different schematic routes to such scaffolds were identified 
(FIGURE 28B-D). In the first route (FIGURE 28B), the nucleophilic carbon atom in the exo-
enaminone intermediate attacks a carbonyl function with a leaving group being expelled to form 
the second ring. In the second route (FIGURE 28C), the nucleophilic nitrogen in a protected 
enaminone derivative attacks an electrophilic carbon in a ring closure process. In the third route 
(FIGURE 28D), the nitrogen attacks the carbonyl group present in the ring and via an 
intramolecular imine formation the exo- and endo-enaminone bicyclic scaffold is afforded.  
 
FIGURE 28. A) Initially, efforts were made to synthesize a diketo-based bicyclic scaffold starting from N-protected 
3,5-dioxopiperidone. Three reaction routes can be rationalized, either B) and C) via exo-enaminones as intermediates 
or D) via a trioxo derivative. 
All three routes were screened and evaluated. In SCHEME 21, alloc-protected 3,5-dioxopiperidine (94) was 
reacted with a diester of L-Asp to afford (S)-95, as described in the literature.57 The t-butyl group was 
selectively removed by TFA/DCM to give (S)-96. Attempts to pre-activate an intramolecular reaction 
proved to be difficult. Pre-activation of the carboxylic acid via acid chloride, anhydride or DCC was tested 
but no ring closure to (S)-97 was detected (NMR).  
 
SCHEME 21. Reagents and conditions: i) L-Asp(tBu)OMe, Et3N, C6H6/NMP 9:1, MW 5 min @ 140 ºC; ii) 
TFA/DCM, 0 ºC => rt, 16 h (quant. yield); iii) see text (no isolated product). 
Instead, the second strategy was tested (SCHEME 22). The alloc-protected 94 was reacted with benzyl 
amine to afford the N-protected exo-enaminone 98 in 29%. Attempts to react 98 with trans-crotonyl 
chloride mediated by Et3N in xylene did however not afford any product. To test the reaction in another 
system, dimedone (99) was used as the starting material and was reacted with benzyl amine to obtain 100. 
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Thereafter, 100 and t-crotonyl chloride were refluxed for 5 hours to give 101, the heating was continued 
overnight but no ring closure was observed (NMR). 
 
SCHEME 22. Reagents and conditions: i) Benzyl amine, 98: Et3N, C6H6/NMP 9:1, MW 5 min @ 140 ºC (29%), 
100: p-TSA, toluene, molecular sieves, rt, 16 h; ii) t-crotonyl chloride, Et3N, xylene, reflux, 1 h (48%, over two 
steps); iii) see text (no isolated product). 
In the literature, acyclic starting materials have been used for the same type of aza annulation reactions 
(SCHEME 23).97 The authors claim the need of an electron withdrawing substituent in the R-position. 
Probably, the carbamate used as the protecting group in 98 (SCHEME 22) is not enough for the reaction to 
succeed. The choice of base is also important, the use of pyridine would afford an N-acylated product 
whereas when no base is used primarily 2-pyridone is formed.98 
O
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SCHEME 23. Literature example of acyclic starting material in an aza-annulation reaction.97 Reagents and 
conditions: i) Et3N, xylene, reflux 2 and 8 h. 
Recently, a cyclization reaction was reported starting from dimedone and an α,β-unsaturated aldehyde 
derivative affording a dimedone-based bicyclic scaffold, although with aromatic substituents (SCHEME 
24).99 
 
SCHEME 24. Recently reported synthesis to a dimedone-based bicyclic scaffold.99 Reagents and conditions: i) 
toluene, reflux, 6-8 h (90%). 
 
Eventually, the third strategy was tried (FIGURE 28D). Thus, 94 was used together with DMAP and DCC-
activated Boc-L-Asp(COOH)OtBu to afford the trioxo intermediate 102 but only traces of product were 
observed together with unreacted starting materials (LC/MS) (SCHEME 25). However, when 
benzyloxycarbonyl (Cbz) was used as the protecting group of 3,5-dioxopiperidine (103) 104 could be 
isolated in 7% yield (SCHEME 25). Using DIC as the coupling reagent did not improve the yield according 
to LC/MS analysis of the reaction mixture. 
44 
 
 
SCHEME 25. Reagents and conditions: i) DCC, DMAP, Boc-N-L-Asp(COOH)OtBu, DCM, rt, on.  
 
Instead, dimedone was reacted with DCC-activated Boc-N-L-Asp(COOH)OtBu to afford intermediate (S)-
105 in a high yield (83%) (SCHEME 26).100 Interestingly, the yields differ more than ten times depending 
on the choice of starting material. This means that the nitrogen atom in 94 affects the reactivity negatively. 
The choice of protecting groups (Cbz or alloc) did not seem to improve the yield either. However, there 
are more protecting groups that can be scanned in order to try to improve the yield of a piperidine-based 
bicyclic compound, e.g. benzyl or tosyl.101 1H NMR spectrum of (S)-105 showed a sharp peak at 17 ppm 
revealing a strong hydrogen bond between an enol proton and a carbonyl group. A 13C NMR spectral 
assignment of the signals for (S)-105 (in CDCl3) showed that the dimedone ring is asymmetrically 
arranged with one enol and one keto function (SCHEME 26). 
 
SCHEME 26. Reagents and conditions: i) DCC, DMAP, DCM, Boc-N-L-Asp(COOH)OtBu, rt, 7 h; or Boc-N-L-
Asp(COOH)NH2, rt, 16 h; or Boc-N-β-Ala, rt, 16 h; ii) HCl/dioxane 4N, rt, 1-3 h; iii) chloroform, (S)-106: rt, 4 days 
(90%) or 45 ºC, 5 h (81%); (S)-110: reflux, 5 h; 112: diluted reaction mixture (3.2 mM), 45 ºC, 18 h. 
 
The focus was now turned to the dimedone-based bicyclic scaffold. To continue, the Boc protecting group 
of (S)-105 was selectively removed using hydrochloric acid in dioxane (4N) to give the unprotected 
intermediate without affecting the tert-butyl ester (SCHEME 26). (S)-106 was formed spontaneously in 
CDCl3 when unprotected (S)-105 was left in an NMR tube for 72 h, and appeared as a dark red solution. In 
order to decrease the reaction time, Boc-deprotected (S)-105 was refluxed in toluene using either a Dean-
Stark trap or microwave-assisted heating but no conversion of the starting material was observed. To 
investigate the reaction in more detail an NMR tube was loaded with a CDCl3-solution of Boc-deprotected 
(S)-105 and heated (45 ºC) by the NMR heating device while 1H and 13C NMR spectra were recorded 
every hour. The experiment revealed complete conversion after five hours (FIGURE 29). 
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FIGURE 29. 13C NMR spectra of the formation of (S)-106 in CDCl3, recorded at A-E) 0, 2, 3, 5 and 10 h while 
heating (45 ºC); F) spectrum of purified 106b. 
The reaction was later performed in large scale (4.0 g) with heating using a traditional oil bath to yield (S)-
106 (81%). Interestingly, depending on the work-up procedure, either simple solvent evaporation or 
washing steps (sat. NaHCO3, followed by brine), the 13C NMR spectra are significantly different 
indicating two isomeric forms of the product. In FIGURE 29F, the 13C spectrum of basified 106b is shown. 
This might indicate that two tautomers of 106 are possible to isolate (FIGURE 30). Possibly, the 
concentrated sample is representing the diketo/enamine structure 106, due to the two carbonyls assign to 
the two peaks above 190 ppm (FIGURE 29E). To assign the basified sample to either the s-cis or s-trans 
enol-imine structure of 106 is more troublesome. Unfortunately, the interpretation of IR measurement 
gave ambiguous results. Attempts to bring the basified 106b back to the dicarbonyl form using acidic 
washings were not successful. The assignment of 106b needs further considerations. 
 
FIGURE 30. Three possible tautomers of (S)-106, the double bonds can either be arranged in a diketo/enamine 
system or an enol/imine system with the single bond either -cis or -trans. 
To continue, the ester function of (S)-106 was cleaved by TFA/DCM to give the corresponding carboxylic 
acid (S)-107 (SCHEME 27). However, subsequent amide coupling with glycine ethyl ester did not give the 
expected product ((S)-108). Instead, two glycine residues react with (S)-107, one forming an amide with 
the carboxylic acid function via the coupling reagents used (PyBOP, HOBt) and one forming an imine 
with one of the carbonyl groups. The structural assignment was not performed. 
 
SCHEME 27. Reagents and conditions: i) TFA/DCM rt, 6 h (quant. yield); ii) PyBOP, HOBt, DIPEA, DCM, rt, 16 
h (a diglycine derivative was isolated instead of the expected product). 
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Instead, attention was turned to the amide (S)-110 (SCHEME 26), by starting from the carboxylic acid (S)-
107 and ammonium acetate. Conversion of starting materials was observed but the mono-amidated 
product could not be isolated due to solubility problems. Instead, dimedone and Boc-N-L-
Asp(COOH)CONH2 were coupled mediated by DCC and DMAP to afford (S)-109 (19%) (SCHEME 26). 
Amide (S)-109 was Boc-deprotected and ring closure was accomplished in refluxing chloroform to yield 
(S)-110. Boc-β-Ala was also coupled to dimedone mediated by DCC and DMAP providing 111 (77%) 
(SCHEME 26). Compound 111 was Boc-deprotected using the same protocol as earlier (HCl/dioxane 4N) 
but the ring closure was considerably slower than the previous ones. Full conversion of Boc-deprotected 
111 was seen after 48 h, but only the non-dehydrated intermediate had formed. In the presence of 
molecular sieves full conversion of 111 was observed after 18 h but only 30% of 112 had formed, the rest 
was assigned to be dimers. Finally, when a diluted solution (50 times) of 111 was heated for 18 h 112 
could be obtained (89%). 
The naphthyridine-like scaffold was envisaged to be synthesized via aza-Diels-Alder reactions.102-103 The 
first cyclization with Danishefsky´s diene and a Boc-protected imine of ethyl glyoxylate in toluene (45 ºC) 
afforded a racemic mixture of the Boc-protected endo-enaminone ((rac)-113) (61%) (SCHEME 28).104-105 
Iodination to 114 and subsequent vinylation mediated by a Stille-coupling formed 115.106 A second Boc-
protected imine was used with 115 for the second aza-Diels Alder cyclization to yield 116 (40%). NMR 
and HPLC analysis (Chiralpak AD) of the product revealed that 116 was formed in a highly regio- and 
stereoselective fashion. Although the structure has three stereogenic centra only two peaks could be seen 
in the HPLC chromatogram. Formation of 1,7-naphthyridine could not be detected. The two Boc-groups 
were successfully removed by TFA/DCM to afford 117. Mono-cyclic 115 was also used with acrylamide 
to afford 118 in a regioselective Diels-Alder cyclization (63%). The Boc-group was removed by 
TFA/DCM to give 119. 
 
SCHEME 28. Reagents and conditions: i) toluene, 45 ºC 18 h; ii) NIS, HTIB, DCM, rt; iii) tributylvinylstannane, 
Pd2(dba)3, AsPPh3, THF, 50 ºC, 2h; iv) toluene, 45-48 ºC, 44 h; v) TFA/DCM, rt, 3h; vi) toluene, 100 ºC, 48h; vii) 
TFA/DCM, rt, 3h. 
The bicyclic compounds (106, 110, 112, 117 and 119) were tested in IdeS and papain inhibition assays  
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5. EVALUATION OF POTENTIAL INHIBITORS 
Synthesized compounds have been tested for their capability to inhibit IdeS, SpeB and papain. 
The inhibition screening was done at the universities in Lund and Umeå. Measurements of pKa 
values have been performed on a small selection of compounds at AstraZeneca R&D, Sweden. In 
silico docking experiments have been performed to try to explain the outcome of the test results of 
the peptides and piperidine-based analogues. 
 
5.1 INHIBITION SCREENING (PAPER I, III, IV) 
To perform the inhibition screening, the compounds to be tested were pre-mixed with the enzyme 
and incubated at room temperature. The substrate was added followed by another incubation 
period at 37 ºC. Finally, the enzyme activity was quenched prior to samples being analyzed. The 
results are reported as remaining enzyme activity. For SpeB and papain, the assays are based on 
substrate cleavage yielding p-nitroaniline which was used for titrating. For IdeS the only substrate 
known is IgG and the analysis was carried out accordingly. Analysis of IgG cleavage products 
was performed with either surface plasmon resonance spectroscopy and/or gel electrophoresis 
techniques.  
Since there are two scissile bonds in one IgG molecule and either one or two bonds are 
hydrolyzed, different cleavage products can be formed (FIGURE 26). After IdeS hydrolysis the 
heavy chains are held together by disulfide bridges, sugar moieties and also hydrophobic 
interactions. Consequently, the mono-cleaved IgG is difficult to distinguish from the intact IgG. 
Conditions during the analysis also affect the cleavage products further. When sugar molecules 
have been removed the cleavage products are held together by disulfide bridges and one or two 
fragments (25 kDa) are released from the mono-cleaved or double-cleaved IgG, respectively 
(FIGURE 26B). When the disulfide bridges also have been removed, all four chains are separated 
(FIGURE 26C). The heavy chain weighs 56 kDa, both the light chain and the cleaved-off fragment 
weigh 25 kDa, the rest ( = 56-25) is a 31-kDa fragment. 
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FIGURE 31. Schematic picture of intact IgG and cleavage products. A) Sugar moieties and disulfide bridges 
present; B) Sugar moieties absent but disulfide bridges present; C) Both the sugar moieties and disulfide bridges are 
absent. 
Surface Plasmon Resonance (SPR) spectroscopy is based on an optical phenomenon used to 
measure interactions between two molecular species, one in solution and one stationary, attached 
at a specific surface. The method is implemented in a Biacore instrument (FIGURE 32A) and is 
applicable for binding affinity site analysis, kinetic studies and as in this thesis, concentration 
measurements of IgG.107-108 The optical phenomenon is based on electron scintillation at a metal 
surface on a chip and is triggered by the energy from a light beam (FIGURE 32B). One side of the 
chip is covered with a thin gold film and on the other side the stationary species is covalently 
attached, in our case protein A. The protein A-side is part of the flow cell wall. Next to the gold 
film is a glass prism. When a light beam is passed through the prism, it becomes reflected by the 
gold surface and is received by a photo detector. The reflection is highly sensitive to the 
microenvironment in the flow cell. The microenvironment is changed as a solution with IgG is 
passing through the flow cell and intact IgG binds to protein A. When IgG binds, the angle is 
shifted. The magnitude of the angular shift is defined as response units (RU) and is an indirect 
measurement of the IgG concentration in the solution. The detection is in real time and a 
sensorgram is obtained (FIGURE 32C).  
In the inhibition assay, two samples are withdrawn at t0 ( = substrate addition) and at t20 min, 
sequentially injected and then compared. If the gap between the graphs is large, less IgG is intact 
after 20 min and more IgG has been cleaved, which means that IdeS is active and the inhibition is 
low. If the gap is small, most IgG molecules are still intact, which means that IdeS is inactivated 
and the inhibition is strong. The conditions used during SPR analysis leave both the disulfide 
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bridges and the sugar moieties unaffected (cf. FIGURE 31A). SPR cannot distinguish intact from 
mono-cleaved IgG as both interact with protein A. Consequently, SPR analysis will only reflect 
inhibition of the second cleavage. 
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FIGURE 32. A) Biacore instrument used for SPR spectroscopy; B) the detection unit; C) sensorgram with two 
graphs from  samples withdrawn at t0 and t20min. Comparison is done when steady state is reached.  
The SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) technique uses 
electric current to separate negatively charged proteins. A correlation between charge and 
molecular weight means that proteins migrate differently according to their weight.109 When the 
gel is stained (Coomassie blue), bands with proteins become visible and evaluation of the 
migrated distances is possible. The shorter migrated distance the higher molecular weight 
(starting from the top, FIGURE 33). Different gels separate IgG and its cleavage products 
according to the discussion above. Gels with reducing conditions will show the IgG chains 
separately (FIGURE 33).  
28 kDa
ladderIgG
+IdeS
+inhibitor
IgG
+IdeS
IgG
56 kDa
36 kDa
 
FIGURE 33. A schematic stained gel used in SDS-PAGE separation technique under reducing conditions, showing 
proteins as bands separated due to migration according to their weight. Fragments of intact but reduced IgG show 
two bands at 25 and 56 kDa. IdeS itself appears as a band of 36 kDa and the totally cleaved IgG shows bands at 31 
and 25 kDa.  
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For IgG, both the light chain and the cleaved-off fragments weigh 25 kDa, the amount of the 
remaining 31 kDa-fragment is a measurement of IdeS activity. When IdeS is totally inhibited IgG 
is intact.  
Gradient gels with non-reducing conditions can differentiate the fragments shown in FIGURE 31B, 
as intact IgG, mono-cleaved IgG and F(ab´)2 have different molecular weights. Hence, the first 
cleavage of IgG can be detected by SDS-PAGE under non-reducing conditions. 
5.2 TPCK/TLCK ANALOGUES AS IdeS INHIBITORS (PAPER I) 
TPCK/TLCK analogues (2-3, 5-7, 26-33) were evaluated as inhibitors of IdeS (FIGURE 34). Also 
two aziridines (4b-c) were tested. 
 
 
FIGURE 34. TPCK/TLCK, 2-3, 5-7, 26-33 and aziridines 4b-4c tested for IdeS inhibition capacity. Different R-
substituents are seen horizontally and the varied warhead functionalities vertically. 
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The samples were analyzed by SDS-PAGE under reducing conditions and TPCK and TLCK 
were included as positive controls and E-64 as a negative control (FIGURE 35A-C). Visual 
inspection of the stained gels showed that eight of the 25 compounds tested were able to inhibit 
IdeS. Compounds 7a-c and 30 with aldehyde function as the warhead were identified as 
inhibitors of IdeS. In comparison, the known irreversible inhibitors TPCK/TLCK show the same 
degree of inhibition as 7a-c and 30. As no 31 kDa-fragment is observed, IdeS is totally inhibited. 
No differentiation of inhibition potency can therefore be made for the different R-groups in 7a-c 
and 30. Five nitrile derivatives were tested but only 6b was identified to inhibit IdeS. Out of all 
the R-substituents used together with the nitrile warhead only the combination of n-butyl and 
nitrile could affect IdeS. This implies that the n-butyl derivative is able to interact strongest with 
IdeS, and that a straight aliphatic side-chain is preferred. 
 
 
 
FIGURE 35A-C. Evaluation of TPCK/TLCK analogues (2-3, 5-7, 26-33 and 4b-c) as inhibitors of IdeS by SDS-
PAGE under reducing conditions. Also shown, IdeS and IgG mixed and separated, as well as TPCK/TLCK and E-
64.  
In addition, the TPCK analogues with an azide warhead, 3a-c, were identified as moderate 
inhibitors of IdeS. However, no ranking among them can be done. In contrast, the TLCK 
analogues 29 and 33 did not inhibit IdeS. This means that apolar R-groups are more favorable 
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than polar ones, as also was suggested for the nitrile warheads. Photolytic decomposition of 
reported azide derivatives used for inhibiting cysteine proteases prompted a stability test.56 Azide 
derivative 3c was, however, shown to be stable in the solid state and in buffer solutions at the 
experimental conditions for 48 h according to both 1H NMR and HPLC analysis. 
None of the other compounds tested was able to inhibit IdeS. That is, the compounds with 
functions such as alcohol (1a-c, 26, 31), tosyloxy (5a-c, 27) or the aziridines (4b, 4c) (data not 
shown) were not useful for inhibition of IdeS. Apparently, tosylesters and the aziridines did not 
react with Cys94 in the IdeS active site. Also, compounds containing hydrogen-bond donors (or 
acceptors) that do not find complementary binding partners are strongly disfavored in overall 
binding. Steric hindrance and unfavorable spatial orientation might also be explanations for their 
inability to inhibit IdeS. 
In summary, all four aldehydes, one nitrile and three azide derivatives were identified as 
inhibitors of IdeS. As seen, hydrophobic interactions between the inhibitor´s R-group and the 
enzyme contribute to the binding. For substructures resembling TPCK/TLCK the warhead 
functionality is still important but irreversible covalent binding is not needed. All the aldehyde 
derivatives showed inhibitory potency as strong as the irreversible covalently bound 
TPCK/TLCK. Thus, reversible binding of 7a-c and 30 is strong enough to compete with IgG for 
the active site and to inhibit IdeS. 
 
5.3 PEPTIDES and PIPERIDINE ANALOGUES AS INHIBITORS (PAPER III) 
5.3.1 IdeS 
The purchased peptides were based on the amino acid sequence of IgG and were extended either 
N- or C-terminally from the cleavage site in IgG, or symmetrically to both sides (FIGURE 31). All 
peptides were found to be inactive as inhibitors of IdeS (data not shown). Although the sequences 
of the tested peptides are identical to the IgG sequence around the IdeS cleavage site these short 
peptides are not recognized by IdeS or are at least not interacting strongly enough to inhibit the 
enzyme. Perhaps the catalytic site is not accessible for the peptides, due to Arg259 residue 
hinderence. 
 
FIGURE 36. Sequences of tested peptides, GG represent the cleavage site of IdeS and SpeB. 
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The di-, tri- and tetrapeptide analogues and also X and (rac)-81 were screened for their 
inhibition capacity against IdeS and analysed by SDS-PAGE with non-reducing gels.  
 
FIGURE 37. Di-, tri- and tetrapeptide analogues of GG, LLGG and LGGP peptide sequences tested for inhibition 
capacity. (R)- and (S)- refer to the configuration of the formed stereogenic center. All amino acids used have the S-
configuration, if chiral. 
It was found that the analogues with inhibition capability all inhibited the second IgG cleavage 
step of IdeS. In FIGURE 38, for both (S)-70 and the reference lane, no intact IgG is present due to 
the first cleavage. Comparison of (S)-70 and the reference shows that the band corresponding to 
single cleaved fragments are thicker in the (S)-70 lane, due to inhibition of IdeS second cleavage. 
 
FIGURE 38. Representative SDS-PAGE analysis using non-reducing gel showing non-hydrolyzed intact, single and 
double cleaved IgG in the presence of inhibitor (S)-70 and without (DMSO). 
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When analysing the inhibition data further, using SPR technique, three groups could be 
distinguished (FIGURE 39). A cut-off value of 80% IdeS remaining activity was set, analogues 
with higher remaining activity were considered unable to inhibit IdeS.  
 
FIGURE 39. IdeS remaining activity in the presence of peptide or peptide analogue. Remaining activity is expressed 
relative to a standard curve obtained in absence of inhibitors. 
Another limit was set at 60%. Analogues with 60-80% remaining activity were considered 
moderate inhibitors and analogues showing 60% or less remaining IdeS activity were considered 
as strong inhibitors of IdeS. The most potent inhibitors of IdeS are (S)- and (R)-84 (pipGP), (S)-
70 (pipG), (S)-86 (LpipGP) and (R)-74 (LpipG). This implies that extension of the pip236G 
fragment towards the C-terminal is favoured. 
The unsaturated pip236G analogue X was also screened but showed no inhibition capacity, even 
though the structural resemblance with (R)- and (S)-70 is high (data not shown). However, the 
unsaturated ring is less flexible than the piperidine ring and the double bond provides an altered 
electron density of the enamine, which possibly results in less efficient hydrogen bonding. Also 
(rac)-81 (pipA) is structurally similar to (R)- and (S)-70 but the racemic mixture was not able to 
inhibit IdeS (data not shown). The additional methyl group in (rac)-81 seems to hinder the 
efficient binding compared to (R)-70. 
There are two sets of LGGP analogues, with the piperidine moiety substituting either of the two 
glycine residues. Comparison of the LGGP analogues showed that the Lpip236GP analogues (S)- 
and (R)-86 are stronger inhibitors than the LGpip237P analogues, (S)- and (R)-90. There is even 
larger difference for the tripeptidic GGP analogues, the pip236GP analogues (S)- and (R)-84 are 
much stronger inhibitors than the corresponding Gpip237P derivatives, (S)- and (R)-88. The 
difference in distribution of the hydrogen bonding possibilities of the structures of the pip236 and 
pip237-analogues may be an explanation to the potency difference. Also, sterical interactions and 
the flexibility of the two sets differ. 
The (R)- and (S)-isomers of each analogue pair show different inhibition, although the difference 
in potency is small. For di- and tetrapeptide analogues the (R)-isomers show stronger inhibition 
than the corresponding (S)-isomers. The relationship is reversed for the tripeptide analogues. 
Actually, the only exception is pip236GP where (R)-84 is equipotent with (S)-84. The largest 
difference is seen for the LLpip236G analogues, favouring (S)-77. This result is not easy to explain 
but could indicate that analogues of different lengths find different binding poses. 
The ethylated analogues (R)- and (S)-93 are equipotent with (S)-77. This implies that the NH-
group of the secondary amine in (S)-77 is not involved in hydrogen bonding and that the 
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replacement of the hydrogen with an ethyl group favours the overall binding. This also means 
that there must be space enough for the ethyl group. 
Interestingly, the structural difference between the (S)-analogues of Lpip236GP and pip236G is two 
amino acids but still the two compounds (S)-86 and (S)-70 are equipotent. The extra amino acids 
are not providing any additional interactions to gain stronger binding, or are too flexible to gain 
favorable binding energies. With ligand efficiency in mind, where binding energy per atom is 
evaluated, this means that (S)-70 (pip236G) is the most efficient peptide analogue inhibitor in the 
whole series.110 
 
5.3.1 papain/SpeB 
To gain insight into whether the peptide analogues are capable of inhibiting IdeS selectively, all 
peptides and peptide analogues were also screened in enzyme activity assays using SpeB and 
papain. 
 
FIGURE 40. Inhibition capacity of peptides and peptide analogues of SpeB (0.28 μM inhibitor). SpeB activity is 
expressed relative to enzyme activity in absence of inhibitors. 
Using a cut-off value of 80% remaining SpeB activity, six compounds were shown to be able to 
inhibit SpeB (FIGURE 40). Actually, also the LLGG peptide inhibits SpeB to some extent. With a 
cut-off value of 60% only the ethylated LLpip236EtG analogue (R)-93 inhibited SpeB. In addition, 
and in contrast to the effect observed for IdeS, also the LGpip237P analogues (R)- and (S)-90 
inhibited SpeB activity. These analogues contain a similar tertiary amine fragment as the 
ethylated analogues. Thus, the absence of a hydrogen bond donating group and the rigid structure 
of the neighboring piperidine and proline rings appear to increase the interaction between (R)- 
and (S)-90 and SpeB. Not surprisingly, the more flexible Lpip236GP analogues (R)- and (S)-86 do 
not affect SpeB activity. 
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FIGURE 41. Inhibition capacity of peptides and peptide analogues of papain (0.9 μM inhibitor). Remaining activity 
is expressed relative to enzyme activity in absence of putative inhibitors. 
As the result from the papain inhibition assay performed with the peptide analogues shows, 
papain was clearly very sensitive towards most compounds tested (FIGURE 41). With a cut-off 
value of 80% remaining activity, all but one compound ((R)-74) were able to inhibit papain. Also 
the peptides LLGG and LGGP acted as inhibitors, although the enzyme preferentially binds other 
residues in the active site. A cut-off value of 20% shows that Gpip237P analogues ((R)-90, (S)-90,   
(R)-88 and (S)-88) are the strongest papain inhibitors. Interestingly, comparison of the GG 
peptide and the pip236G analogues (R)- and (S)-70 show a large difference in potency, with the 
dipeptide GG being the most potent. 
In summary, the most active inhibitors of IdeS, (R)-84 and (S)-86 are even more active towards 
papain, but show no inhibitory activity towards SpeB. Finally, both (R)- and (S)-70 as well as 
(R)- and (S)-74 show promising selectivity profiles as they are both potent inhibitors of IdeS but 
are hardly affecting papain and do not inhibit SpeB. 
5.3.3 pKa measurements 
The pKa-value for the primary amine in the amino acid leucine is 9.7. For a dipeptide Leu-Xaa, 
with Xaa being either Gly, Phe or Leu, the corresponding value is decreased by 1.5 units, to 
~8.4.111 The primary amine in 86 shows a value as low as ~ 5. Also, the pKa value of piperidine is 
11.22 meanwhile piperazine (5.56 and 9.83) shows reduced basicity for both amine functions. 
The predicted and determined pKa-values for the epimers of 70 and 86 are shown in TABLE 5.112 
Interestingly, the two pKa values for each compound differ considerably. The acyclic secondary 
amine is not protonated at physiological pH and thus able to act both as a hydrogen bond donor 
and acceptor. 
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TABLE 5. pKa values for the pip236G (70) and Lpip236GP analogues (86).a 
 
 measured predicted 
cmpd pKa1 pKa2 pKa1 pKa2
(R)-70 4.41 10.11 5.40 9.84 
(S)-70 4.35 10.06   
(R)-86 5.13 8.46 7.35 9.13 
(S)-86 5.21 8.53   
aDetermination of pKa-values performed  by a 
screening method based on pressure-assisted 
capillary electrophoresis and mass spectroscopy. 
 
5.3.4 In Silico dockings of peptides and peptide analogues in IdeS 
The active site of the crystal structures of IdeS available for in silico docking studies is occupied 
by either a sulphate ion or mercaptoethanol. Obviously, a substrate would directly be hydrolyzed 
when used together with the active enzyme. Without a ligand in the active site, a clear judgment 
of the agreement with an active and operative enzyme is highly difficult to make. The fact that two 
independent research groups prepared the available structures of IdeS, which to a high extent 
resemble each other, is an argument for the correctness of the structures. That said, the structure 
present in solution and in a solid crystal may not be the same. A structure derived by X-ray 
spectroscopy of a protein crystal is one single snap-shot of a long series of movements that 
eventually lead to a cleaved substrate. The fact that the side-chain of Arg259 intrudes into or 
covers the active site in the available X-ray structures and thus physically hinders a substrate to 
bind in a productive way conceals the picture and increases the challenge of structure-based 
design and also evaluation.113 
The two structures of IdeS with PDB ID 1Y08 and 2AU1 have been compared and an overlay of 
the two enzyme structures reveals some important differences (FIGURE 42).  
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FIGURE 42. Comparison of structures; 1Y0A (green) and 2AU1 (grey). View from “front” (left) and “back” (right). 
The thicker back-bone the more movement of the residues. 
The side chain of Arg259 is positioned differently, but both hinder binding through the active site. 
The aromatic ring of Phe172 adopts different positions due to rotation. However, preliminary 
docking results showed that the docked poses of peptide analogues were not affected by the 
rotation of Phe172. Further, three residues close to the active site did not provide enough 
diffraction data during X-ray spectroscopy measurement due to high flexibility and are thus not 
present in the 1Y0A-structure, however they are present in the 2AU1-structure. The thickness of 
the back bone of the structures shown in FIGURE 42 is correlated to the R-value, a measurement of 
relative movements in proteins. Although the R-values for 1Y08 and 2AU1 are considered to be 
low, the movement close to the active site is most pronounced. 
Dockings were performed using three different versions of the active site of the 2AU1 structure. 
In two versions the catalytic cysteine residue was either anionic or neutral. The third version also 
included a neutral cysteine residue but here the Asn261 side chain was flipped. The Arg259 side 
chain was removed in all three versions. 
Different lengths of peptides were docked. As the peptides resemble a part of the IgG hinge 
sequence, they should show a “productive binding pose” where the nucleophilic sulphur in Cys94 
should be able to reach the carbonyl group of the scissile amide bond in a Bürger-Dunitz fashion. 
Some of the docked peptides do find such a pose through the active site, but not all. In fact, even 
though LGGP is only a tetrapeptide, the docked poses with the scissile bond in the vicinity of 
Cys94 may indicate how IgG is placed when being cleaved.  
The Lpip236GP analogues (R)- and (S)-86 were also docked. Surprisingly, none of the poses were 
docked through the catalytic site. It seems that the piperidine moiety is too large to fit in the 
catalytic site, close to Cys94. The docked poses for both the peptide LGGP and the analogue (R)-
86 (Lpip236GP ) in the 2AU1-structure are shown in FIGURE 43. Other binding sites found by the 
analogues are either placing a part of the compound into the shallow pocket to the right or to the 
left. The analogues of pip236G (R)- and (S)-70 were also docked. Even though the glycine moiety 
reached into the active site the piperidine moiety did not, implying that the walls above the active 
site are too narrow for such a binding pose.  
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FIGURE 43. In silico docking poses of peptide LGGP (yellow) and (R)-86 (Lpip236GP, orange) in IdeS (2AU1). 
Taken together, these findings indicate that the analogues interact differently with the enzyme 
compared to the peptides and thus also different to the IgG peptide sequence. IgG is cleaved by 
IdeS and must therefore bind through the active site. The peptides can find poses through the 
active site but are not able to inhibit IdeS. To explain the inability of the peptides to inhibit IdeS it 
can be speculated that peptides bind to the enzyme but too weakly, or that the peptides do bind 
but are easily replaced by IgG or even by the side-chain of Arg259. Several of the analogues are 
inhibiting IdeS, possibly not by binding through the active site but by other poses.  
5.4 BICYCLIC COMPOUNDS as INHIBITORS (PAPER IV) 
Bicyclic compounds (106, 110, 112, 117 and 119) was evaluated as IdeS and papain inhibitors (FIGURE 
44). 
 
FIGURE 44. Dimedone-based and 1,8-naphthyridine and quinolone-like scaffolds tested as inhibitors in IdeS and 
papain assays. 
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For IdeS about 70% of the activity remained during the inihibition assay with 117 and 119, 
compared to that of the DMSO control (FIGURE 45A). In contrast, papain was nearly totally 
inhibited by 117 during the condition used and 119 decreased the papain activity to ~15% 
(FIGURE 45B). Both compounds showed greater inhibition towards papain than IdeS. 
 
FIGURE 45. Remaining A) IdeS and B) papain activity in the presence of 117 and 118 and substrate. 
A cut-off value of 80% remaining papain activity shows that 110 and 112 have none or moderate 
inhibition capacity (FIGURE 46). The base-treated 106c is not affecting papain (FIGURE 46) 
whereas 106a induces a strong inhibition. Result from the IdeS inhibition assay (data not shown) 
gave the same activity profile as shown for papain for both 106a and 106c. Thus, 106a inhibits 
IdeS but no selectivity towards papain was obtained. 
 
FIGURE 46. Inhibition capacity of 106, 110 and 112 of papain (0.28 M inhibitor). Remaining activity is expressed 
relative to enzyme activity in absence of putative inhibitors. a, b, and c represent different work-up procedures. 
In contrast, the three samples of 112 showed moderate capacity of papain inhibition, but gave 
surprising result in the IdeS assay. Therefore, a SDS–PAGE assay with non-reducing gels was 
employed to be able to distinguish the single cleaved and double cleaved IgG (FIGURE 47).114 
Rapid cleavage of IgG is observed already after 20 s and only a small amount of intact IgG is still 
present at this time point. Single-cleaved IgG is accumulated, while only little F(ab´)2-fragment 
can be observed, meaning the second cleavage have not yet occurred. In contrast, at time point 20 
min, nearly no intact IgG is left and the ratio of single and double cleaved IgG is approximately 
1:1. This means that the second cleavage is much slower under the conditions used. Importantly, 
the two IdeS mediated hydrolysis steps occur sequentially. 
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FIGURE 47. SDS-PAGE analysis (non-reducing gel) of a time-study of IdeS mediated cleavage of IgG. 
In FIGURE 48, the SDS-PAGE analysis with non-reduced gel shows that 112 is a very strong 
inhibitor of IdeS. The concentrated 112a prevents the second hydrolysis of IgG to occur. The 
basified 112c inhibits also the first hydrolysis step, a IdeS mediated hydrolysis usually performed 
in 20 seconds! In fact, 112c inhibition results in intact and mono-cleaved IgG but no F(ab´)2-
fragment at all. The second hydrolysis does not occur. 
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FIGURE 48. SDS-PAGE (non-reducing gel) analysis of 112, prepared by different worked-up conditions a) 
concentrated, b) brine-wash and c) basic aqueous-wash. 
In summary, five bicyclic compounds with three different scaffolds have been screened for their 
capacity of inhibition of IdeS and papain. 117 and 119 are strong inhibitors of papain and are 
shown to be selective towards IdeS. The dimedone-based compounds 106 and 112 show different 
activity profiles. Whereas 106 show either strong or no inhibition of both IdeS and papain 
depending on the  work-up procedure, 112 show a very strong inhibition capacity of IdeS with 
moderate selectivity towards papain. Further evaluation of these highly interesting results must 
await the assignment of the structures. That said, the different structures of 112 assigned during 
NMR spectroscopy conditions or elsewhere do not necessarily correlate to conditions used in the 
inhibition assays. 
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6. SUMMARY and OUTLOOK 
 
The bacterial cysteine protease IdeS was discovered ten years ago. It is considered highly 
interesting to use for therapeutic applications in autoimmune diseases due to its IgG-proteolytic 
ability, but it might also be of interest as a target for novel treatments of acute and severe 
bacterial infections. In this thesis several compounds have been synthesized that show IdeS 
inhibitory capacity, which can serve as a starting point for further development. 
In the TPCK/TLCK project, synthetic routes were developed that allowed the synthesis of several 
TPCK/TLCK analogues. Eight compounds were identified to be IdeS inhibitors and some SAR 
conclusions could be drawn. In contrast to papain, IdeS is affected by p-toluylsulfonamide 
derivatives with lipophilic R-substituents. The questions asked at the outset of this project could 
be answered; the irreversible warhead is not needed for inhibition since the reversible aldehyde 
derivatives inhibit IdeS as efficiently as TPCK and TLCK. The R group substituent does 
contribute to the inhibitory effect, n-butyl is considerably better than the more polar 4-aminobutyl 
moiety. 
A synthetic route to the peptide analogues was developed based on reductive amination to 
introduce the stereogenic center in the first step. Determination of the absolute configuration of 
the initially formed products allowed the assignment of the absolute configurations of all final 
test compounds. No racemization was detected in any of the synthetic steps. In a substrate based 
approach several di-, tri- and tetrapeptide analogues of GG, LGG, GGP, LLGG, and LGGP, 
which cover the IdeS cleavage site in IgG, were synthesized. Either of the two glycine residues 
was replaced by a 3-aminopiperidine moiety, a new peptidomimetic fragment. All compounds 
were screened for their capability to inhibit IdeS, SpeB and papain. Several compounds were 
identified as inhibitors, five compounds showed 50% remaining IdeS activity at 0.8 μM. The 
small difference in potency makes a full SAR analysis difficult for the peptide analogues, but an 
extension C-terminally in pip236G seems to favor activity. However, for increased selectivity 
against related cysteine proteases an extension N-terminally is suggested, as shown by the di- and 
tripeptide analogues pip236G ((S)-70) and Lpip236G ((R)-74). Eight peptides covering the IdeS 
cleavage site of IgG were found to affect IdeS activity. In silico dockings were performed to 
elucidate the origin of the different activity profiles. The result indicates that the two sets of 
compounds find different binding sites. The X-ray structure used in the docking studies cannot 
accommodate the piperidine moiety in the catalytic site. Whether this is true also in solution 
needs more thorough investigations. NMR spectroscopic studies of IdeS are on-going, by 
understanding how IdeS interacts with an inhibitor, development of inhibitors with stronger 
potency will be possible. 
The interesting inhibition profiles of pip236G ((S)-70) and Lpip236G ((R)-74) motivated the 
synthesis of novel bicyclic compounds. The strategy was to rigidify the structures and thereby 
increase the potency. Initially, piperidine-3,5-dione was considered as the starting material, but 
low product formation prompted new routes. Interestingly, when using dimedone as starting 
material, i.e. an analogue of piperidine-3,5-dione in which the nitrogen is replaced by a carbon 
atom, the yield increased more than ten times. It might be possible to optimize the yields starting 
also from piperidine-3,5-dione by altering the protecting group, but this was not further pursued 
in this thesis work. The structures of the synthesized bicyclic derivatives all comprise an 
enaminone function which seems to isomerize into different tautomeric forms. The detailed 
composition of such isomeric mixtures is not yet fully assigned, for that further actions are 
needed. Five bicyclic compounds based on quinolinone and naphthyridinone scaffolds were 
tested for their inhibitory potency on IdeS and papain. The naphthyridine derivatives were able to 
inhibit papain selectively over IdeS. One quinolin-4,6-dione derivative (112) showed very strong 
IdeS potency, it inhibited IdeS already in the first step of the IgG hydrolysis – a catalytic process 
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usually finished in 20 seconds! This compound should serve as a good starting point for further 
development of more potent and more selective IdeS inhibitors. Its selectivity against human 
cysteine proteases also needs to be investigated.  
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8. APPENDICES 
APPENDIX 1 
Determination of the absolute configuration of 68, 63 and 41.  
In order to determine the absolute configuration of the two diastereomers of 68, formed with the 
highest ratio (21:79), the mixture of (1)- and (2)-68 was separated using preparative HPLC 
(Chiralpak AD) (SCHEME A1). The excess isomer (2)-68 was crystallized from n-hexane. 
However, the flake-shaped crystals could not be used to produce satisfactory X-ray diffraction 
reflections for all three dimensions. Instead, (2)-68 was deprotected using catalytic 
hydrogenation, subsequent Boc-protection afforded diastereomerically pure (1)-63 (SCHEME A1). 
The methyl ester of (1)-63 was aminolyzed into (1)-41 which formed crystals from both n-hexane 
and acetonitrile but enough X-ray data could still not be collected. Instead, reference compounds 
had to be synthesized (SCHEME A1). Starting from enantiopure Boc-protected (S)-piperidinol ((S)-
120) the tosylated intermediate (S)-121 was formed. It was reacted with L-proline amide in an 
SN2 reaction in the presence of pyridine affording only one diastereomer with inverted 
stereochemistry, (RS)-41. For comparison (SS)-41 was also synthesized (not shown). Similar SN2 
reactions with a tosylated secondary alcohol derivative and either L-proline amide or S-piperidine 
carboxamide as the secondary amine have been reported to proceed with inversion.115-116 
Knowing that the absolute configuration of (1)-41 is RS and comparing the retention times from 
HPLC (Chiralpak AD) of both (1)-63 and (2)-68 the diastereomers of these pairs could also be 
unequivocally assigned. 
 
SCHEME A1. (1) and (2) reflects the elution order of the diastereomers from HPLC (Chiralpak AD). Reagents and 
conditions: i) NaBH(O-2-ethylhexanoyl)3 (formed in situ, DCM, rt, on), L-ProlineOMe, molecular sieves, DCM, rt, 
16 h (55%); ii) separation of the diastereomers on HPLC (Chiralpak AD) using hexane/2-propanol 99:1 as the mobile 
phase at a flow rate of 10 mL/min; iii) catalytic hydrogenation (Pd/C), 10 bar, 45 °C, 3 loops in H-cube (86%); iv) 
Boc2O, ethyl acetate/EtOH 1:1, rt, 5 h (96%); v) NH3/MeOH (7N), rt, 48 h (93%); vi) TsCl, DMAP, Et3N, DCM, rt, 
5 h (63%); vii) L-ProlineNH2, pyridine, CH3CN, reflux, 16 h (5%, the rest is unreacted starting material). 
To determine the absolute stereochemistry of 62 the two diastereomers were separated by 
preparative HPLC (Chiralpak AD), and the first eluted diastereomer ((1)-62) was Boc-
deprotected (SCHEME A2). The isolated TFA-salt of 62 was crystallized from THF/hexane and an 
X-ray crystallographic structure determination was performed, which revealed the (SS)-
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configuration (FIGURE A1). Hence, the first eluted diastereomer of 62 also has the (SS)-
configuration. 
 
SCHEME A2. Reagents and conditions: (i) L-AlaOtBu, NaBH(O-2-ethylhexanoyl)3, DCM, rt, 16 h; (ii) preparative 
HPLC (Chiralpak AD); (iii) TFA/DCM, rt, 1h (quant.yield). 
 
FIGURE A1: Ortep picture of the TFA salt of (SS)-122, revealing the absolute configuration of (SS)-62. 
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APPENDIX 2 
The IdeS structure (PDB ID: 2AU1) was prepared according to the Protein Preparation Wizard 
implemented in Maestro, available in the Schrödinger package.117 All water molecules and the 
side-chain of Arg259 were removed. The active site was modified by rotation and protonation to 
optimize the hydrogen bonding between Cys94 and His262. The docking grid was centred to the 
sulphur of the mercaptoethanol moiety located at the active site and a box of 25 Å3 was chosen. 
Ligands were prepared according to LigPrep using OPLS2005, protonation states were used 
according to pKa-measurements (vide infra) and the stereochemistry were kept unchanged. 
Docking calculations were performed in Glide with the standard precision mode (SP) without 
constraints.118 The result was evaluated in a funnel-like fashion. First, all poses were visually 
inspected according to the number of hydrogen bonding possibilities. SiteMap was used for 
characterizing the binding site according to hydrophobic, hydrogen bond accepting or donating 
regions.119 The poses with three or more hydrogen bonds were visually inspected for satisfying 
complementarity of the binding site according to the SiteMap profile. For the most promising 
poses so far, energy calculations were performed to evaluate the strain energy of the docked 
conformers. The energy of the conformer constituting the pose to be evaluated was compared 
with the energy of the most relaxed conformer occupying the global minimum. For 
Conformational Searches and Current Energy calculations in MacroModel OPLS2005, water as 
solvent, PRCG for minimization was used until convergence (0.05) was reached.120 The poses of 
the peptides were also evaluated by distance and Bürger-Dunitz angle (107°) between the sulphur 
atom in Cys94 and the CO-group in the scissile amide bond.121 
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